Gene Annotation
Available parameters and response documentation is available here
GET /lookup/gene/BRAF/hg19?add-source-databases=all
{ "gene_id": 2273, "symbol": "BRAF", "description": "B-Raf proto-oncogene, serine/threonine kinase", "synonyms": [ "BRAF-1", "BRAF1" ], "cgd": { "version": "03-Jul-2024", "pub_med_references": [ 16439621, 16474404, 17483702, 17551924, 18042262, 18413255, 18456719, 19047498, 19206169, 20301303, 20301365, 20523244, 21349766, 21495173, 22946697 ], "condition": "Noonan syndrome 7; Cardiofaciocutaneous syndrome 1; LEOPARD syndrome 3", "inheritance": "AD", "age_group": "Pediatric", "intervention_categories": [ "Cardiovascular", "Hematologic", "Oncologic" ], "comments": "The conditions may be frequently clinically recognized due to characteristic facial features as well as other manifestations", "intervention": null }, "civic": { "version": "08-Dec-2023", "items": [ { "asco_entry": null, "clinical_significance": "Positive", "disease": "Melanoma", "doid": "1909", "drug_interaction_type": null, "drugs": null, "entrez_id": null, "evidence_civic_url": "https://civicdb.org/links/evidence_items/30", "evidence_direction": "Supports", "evidence_level": "B", "evidence_statement": "BRAF mutations are associated with melanoma arising in non-chronic sun damaged skin and with superficial spreading melanoma.", "evidence_status": "accepted", "evidence_type": "Diagnostic", "gene": "BRAF", "gene_civic_url": null, "last_review_date": "2023-01-09 21:46:25 UTC", "nct_ids": null, "normalized_drug": null, "phenotypes": null, "pub_med_references": [ 21166657 ], "rating": "4", "representative_transcript": null, "transcripts": null, "variant": "V600", "variant_civic_url": null, "variant_origin": "Somatic", "variant_summary": null, "gene_description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer. Oncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors. Class 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors. Class 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors. Class 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase." }, { "asco_entry": null, "clinical_significance": "Resistance", "disease": "Colorectal Cancer", "doid": "9256", "drug_interaction_type": null, "drugs": [ "Panitumumab" ], "entrez_id": null, "evidence_civic_url": "https://civicdb.org/links/evidence_items/88", "evidence_direction": "Supports", "evidence_level": "B", "evidence_statement": "In metastatic colorectal cancer patients with wildtype KRAS, BRAF mutations were associated with poor progression free survival regardless of treatment (panitumumab with best supportive care or best supportive care alone).", "evidence_status": "accepted", "evidence_type": "Predictive", "gene": "BRAF", "gene_civic_url": null, "last_review_date": "2023-01-09 21:46:25 UTC", "nct_ids": null, "normalized_drug": [ "Panitumumab" ], "phenotypes": null, "pub_med_references": [ 23325582 ], "rating": "3", "representative_transcript": null, "transcripts": null, "variant": "V600", "variant_civic_url": null, "variant_origin": "Somatic", "variant_summary": null, "gene_description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer. Oncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors. Class 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors. Class 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors. Class 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase." }, { "asco_entry": null, "clinical_significance": "Sensitivity/Response", "disease": "Melanoma", "doid": "1909", "drug_interaction_type": null, "drugs": [ "Trametinib", "Dabrafenib" ], "entrez_id": null, "evidence_civic_url": "https://civicdb.org/links/evidence_items/93", "evidence_direction": "Supports", "evidence_level": "B", "evidence_statement": "This was a Phase I and II study (NCT01072175) of dabrafenib and trametinib combination therapy vs. dabrafenib monotherapy in patients with metastatic melanoma. Cutaneous squamous-cell carcinoma was seen in 7% of patients receiving combination therapy in contrast to 19% in those receiving monotherapy (P = 0.09). Of 162 patients with V600E or V600K mutation, 108 were given combination therapy and 54 monotherapy. After 1 year, 41% of patients in the combination group were alive and progression free whereas this was 9% in the monotherapy group (P<0.001). Median progression-free survival was 9.4 months with combination and 5.8 months with monotherapy. Hazard ratio for progression or death was 0.39 (95% CI, 0.25 to 0.62; P<0.001).", "evidence_status": "accepted", "evidence_type": "Predictive", "gene": "BRAF", "gene_civic_url": null, "last_review_date": "2023-01-09 21:46:25 UTC", "nct_ids": [ "NCT01072175" ], "normalized_drug": [ "Dabrafenib, Trametinib" ], "phenotypes": null, "pub_med_references": [ 23020132 ], "rating": "3", "representative_transcript": null, "transcripts": null, "variant": "V600", "variant_civic_url": null, "variant_origin": "Somatic", "variant_summary": null, "gene_description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer. Oncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors. Class 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors. Class 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors. Class 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase." }, { "asco_entry": null, "clinical_significance": "Positive", "disease": "Thyroid Gland Papillary Carcinoma", "doid": "3969", "drug_interaction_type": null, "drugs": null, "entrez_id": null, "evidence_civic_url": "https://civicdb.org/links/evidence_items/462", "evidence_direction": "Supports", "evidence_level": "B", "evidence_statement": "The AKAP9-BRAF fusion gene was found in 3/28 tumor samples of radiation-associated papillary thyroid carcinoma, and no samples of non-radiation associated papillary thyroid carcinoma. This fusion was associated with elevated BRAF kinase activity, similar to the V600E variant.", "evidence_status": "accepted", "evidence_type": "Diagnostic", "gene": "BRAF", "gene_civic_url": null, "last_review_date": "2023-01-09 21:46:29 UTC", "nct_ids": null, "normalized_drug": null, "phenotypes": null, "pub_med_references": [ 15630448 ], "rating": "4", "representative_transcript": null, "transcripts": null, "variant": "AKAP9::BRAF", "variant_civic_url": null, "variant_origin": "Somatic", "variant_summary": null, "gene_description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer. Oncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors. Class 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors. Class 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors. Class 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase." }, { "asco_entry": null, "clinical_significance": "Sensitivity/Response", "disease": "Melanoma", "doid": "1909", "drug_interaction_type": null, "drugs": [ "Sorafenib" ], "entrez_id": null, "evidence_civic_url": "https://civicdb.org/links/evidence_items/723", "evidence_direction": "Supports", "evidence_level": "C", "evidence_statement": "BRAF fusion AGK-BRAF was associated with decreased sensitivity to vemurafenib and increased sensitivity to sorafenib in-vitro. A single patient with this fusion showed durable response to sorafenib.", "evidence_status": "accepted", "evidence_type": "Predictive", "gene": "BRAF", "gene_civic_url": null, "last_review_date": "2023-01-09 21:46:31 UTC", "nct_ids": null, "normalized_drug": [ "Sorafenib" ], "phenotypes": null, "pub_med_references": [ 23890088 ], "rating": "2", "representative_transcript": null, "transcripts": null, "variant": "AGK::BRAF", "variant_civic_url": null, "variant_origin": "Somatic", "variant_summary": null, "gene_description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer. Oncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors. Class 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors. Class 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors. Class 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase." }, { "asco_entry": null, "clinical_significance": "Resistance", "disease": "Melanoma", "doid": "1909", "drug_interaction_type": null, "drugs": [ "Vemurafenib" ], "entrez_id": null, "evidence_civic_url": "https://civicdb.org/links/evidence_items/724", "evidence_direction": "Supports", "evidence_level": "D", "evidence_statement": "A melanoma cell line with AGK-BRAF in-frame fusion showed decreased sensitivity towards Vemurafenib in comparison with BRAF mutated (V600E) cell lines.", "evidence_status": "accepted", "evidence_type": "Predictive", "gene": "BRAF", "gene_civic_url": null, "last_review_date": "2023-01-09 21:46:31 UTC", "nct_ids": null, "normalized_drug": [ "Vemurafenib" ], "phenotypes": null, "pub_med_references": [ 23890088 ], "rating": "2", "representative_transcript": null, "transcripts": null, "variant": "AGK::BRAF", "variant_civic_url": null, "variant_origin": "Somatic", "variant_summary": null, "gene_description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer. Oncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors. Class 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors. Class 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors. Class 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase." }, { "asco_entry": null, "clinical_significance": "Resistance", "disease": "Melanoma", "doid": "1909", "drug_interaction_type": null, "drugs": [ "Vemurafenib" ], "entrez_id": null, "evidence_civic_url": "https://civicdb.org/links/evidence_items/725", "evidence_direction": "Supports", "evidence_level": "D", "evidence_statement": "BRAF-fusion in \"pan-negative\" melanomas were identified in TCGA data. Cell-lines with PAPSS1-BRAF fusion were resistant to treatment with Vemurafenib.", "evidence_status": "accepted", "evidence_type": "Predictive", "gene": "BRAF", "gene_civic_url": null, "last_review_date": "2023-01-09 21:46:31 UTC", "nct_ids": null, "normalized_drug": [ "Vemurafenib" ], "phenotypes": null, "pub_med_references": [ 24345920 ], "rating": "3", "representative_transcript": null, "transcripts": null, "variant": "PAPSS1::BRAF", "variant_civic_url": null, "variant_origin": "Somatic", "variant_summary": null, "gene_description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer. Oncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors. Class 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors. Class 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors. Class 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase." }, { "asco_entry": null, "clinical_significance": "Sensitivity/Response", "disease": "Melanoma", "doid": "1909", "drug_interaction_type": null, "drugs": [ "Trametinib" ], "entrez_id": null, "evidence_civic_url": "https://civicdb.org/links/evidence_items/726", "evidence_direction": "Supports", "evidence_level": "D", "evidence_statement": "BRAF-fusion in \"pan-negative\" melanomas were identified in TCGA data. Cell-lines with a PAPSS1-BRAF fusion were resistant to treatment with Vemurafenib but sensitive to treatment with Trametinib. This fusion is believed to activate MAPK pathway signaling.", "evidence_status": "accepted", "evidence_type": "Predictive", "gene": "BRAF", "gene_civic_url": null, "last_review_date": "2023-01-09 21:46:31 UTC", "nct_ids": null, "normalized_drug": [ "Trametinib" ], "phenotypes": null, "pub_med_references": [ 24345920 ], "rating": "3", "representative_transcript": null, "transcripts": null, "variant": "PAPSS1::BRAF", "variant_civic_url": null, "variant_origin": "Somatic", "variant_summary": null, "gene_description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer. Oncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors. Class 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors. Class 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors. Class 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase." }, { "asco_entry": null, "clinical_significance": "Sensitivity/Response", "disease": "Melanoma", "doid": "1909", "drug_interaction_type": null, "drugs": [ "Trametinib" ], "entrez_id": null, "evidence_civic_url": "https://civicdb.org/links/evidence_items/727", "evidence_direction": "Supports", "evidence_level": "D", "evidence_statement": "A TRIM24-BRAF fusion was identified in a single patient with metastatic melanoma that was \"pan-negative\" for driver mutations. A cell-line (293H) ectopically expressing the TRIM24-BRAF fusion was found to be sensitive to the MEK-inhibitor Trametinib.", "evidence_status": "accepted", "evidence_type": "Predictive", "gene": "BRAF", "gene_civic_url": null, "last_review_date": "2023-01-09 21:46:31 UTC", "nct_ids": null, "normalized_drug": [ "Trametinib" ], "phenotypes": null, "pub_med_references": [ 24345920 ], "rating": "3", "representative_transcript": null, "transcripts": null, "variant": "TRIM24::BRAF", "variant_civic_url": null, "variant_origin": "Somatic", "variant_summary": null, "gene_description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer. Oncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors. Class 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors. Class 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors. Class 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase." }, { "asco_entry": null, "clinical_significance": "Sensitivity/Response", "disease": "Cancer", "doid": "162", "drug_interaction_type": null, "drugs": [ "Trametinib" ], "entrez_id": null, "evidence_civic_url": "https://civicdb.org/links/evidence_items/936", "evidence_direction": "Supports", "evidence_level": "D", "evidence_statement": "In this screen of 218 solid cancer cell lines, BRAF mutations were predictive of response to the MEK inhibitor GSK1120212. 26 of these cell lines had the BRAF V600E mutation, one cell line had a G469A mutation, one had G596R mutation and one had an unspecified mutation. Also of note, in RAF/RAS mutant colon cancer cell lines, co-occurring PIK3CA/PTEN mutations led to a cytostatic response rather than a cytotoxic response.", "evidence_status": "accepted", "evidence_type": "Predictive", "gene": "BRAF", "gene_civic_url": null, "last_review_date": "2023-01-09 21:46:33 UTC", "nct_ids": null, "normalized_drug": [ "Trametinib" ], "phenotypes": null, "pub_med_references": [ 22169769 ], "rating": "4", "representative_transcript": null, "transcripts": null, "variant": "Mutation", "variant_civic_url": null, "variant_origin": "Somatic", "variant_summary": null, "gene_description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer. Oncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors. Class 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors. Class 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors. Class 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase." }, { "asco_entry": null, "clinical_significance": "Resistance", "disease": "Melanoma", "doid": "1909", "drug_interaction_type": null, "drugs": [ "MEK Inhibitor RO4987655" ], "entrez_id": null, "evidence_civic_url": "https://civicdb.org/links/evidence_items/995", "evidence_direction": "Does Not Support", "evidence_level": "B", "evidence_statement": "Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655. Among 12 patients with melanoma BRAF wild type and non-NRAS or NRAS unknown status, seven patients experienced partial response (n=3) or stable disease (n=4). Authors conclude that RO4987655 has clinical activity in BRAF V600-wt (and BRAF V600E) melanoma. They suggest that other drugs such as immune check point inhibitors are preferred in BRAF wt melanoma, so the role of RO4987655 as a single agent is limited for BRAF WT patients with the possible exception of a small window of opportunity for combinations with MEK inhibitors after immunotherapy progression.", "evidence_status": "accepted", "evidence_type": "Predictive", "gene": "BRAF", "gene_civic_url": null, "last_review_date": "2023-01-09 21:46:33 UTC", "nct_ids": null, "normalized_drug": null, "phenotypes": null, "pub_med_references": [ 24947927 ], "rating": "2", "representative_transcript": null, "transcripts": null, "variant": "WILD TYPE", "variant_civic_url": null, "variant_origin": null, "variant_summary": null, "gene_description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer. Oncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors. Class 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors. Class 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors. Class 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase." }, { "asco_entry": null, "clinical_significance": "Resistance", "disease": "Melanoma", "doid": "1909", "drug_interaction_type": null, "drugs": [ "Refametinib" ], "entrez_id": null, "evidence_civic_url": "https://civicdb.org/links/evidence_items/1000", "evidence_direction": "Supports", "evidence_level": "C", "evidence_statement": "Phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766. 2 of 2 patients with BRAF mutant melanoma had moderate progressive disease (despite receiving the highest doses administered in the study).", "evidence_status": "accepted", "evidence_type": "Predictive", "gene": "BRAF", "gene_civic_url": null, "last_review_date": "2023-01-09 21:46:25 UTC", "nct_ids": null, "normalized_drug": [ "Refametinib" ], "phenotypes": null, "pub_med_references": [ 23434733 ], "rating": "2", "representative_transcript": null, "transcripts": null, "variant": "V600", "variant_civic_url": null, "variant_origin": "Somatic", "variant_summary": null, "gene_description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer. Oncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors. Class 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors. Class 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors. Class 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase." }, { "asco_entry": null, "clinical_significance": "Sensitivity/Response", "disease": "Colorectal Cancer", "doid": "9256", "drug_interaction_type": null, "drugs": [ "Cetuximab", "Panitumumab" ], "entrez_id": null, "evidence_civic_url": "https://civicdb.org/links/evidence_items/1404", "evidence_direction": "Does Not Support", "evidence_level": "B", "evidence_statement": "A quantitative synthesis was performed on nine studies comparing treatment of metastatic colorectal cancer with cetuximab or panitumumab and chemotherapy, versus chemotherapy alone, or with other targeted inhibitors. It was found that in the patient subgroup with BRAF mutation (V600E in the majority of cases), there were no benefits to overall survival, progression free survival, or overall response rate with addition of cetuximab or panitumumab to treatment. This conclusion held in the first line treatment as well as general treatment setting.", "evidence_status": "accepted", "evidence_type": "Predictive", "gene": "BRAF", "gene_civic_url": null, "last_review_date": "2023-01-09 21:46:33 UTC", "nct_ids": null, "normalized_drug": [ "Cetuximab, Panitumumab" ], "phenotypes": null, "pub_med_references": [ 25673558 ], "rating": "3", "representative_transcript": null, "transcripts": null, "variant": "Mutation", "variant_civic_url": null, "variant_origin": "Somatic", "variant_summary": null, "gene_description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer. Oncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors. Class 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors. Class 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors. Class 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase." }, { "asco_entry": null, "clinical_significance": "Sensitivity/Response", "disease": "Melanoma", "doid": "1909", "drug_interaction_type": null, "drugs": [ "Dabrafenib" ], "entrez_id": null, "evidence_civic_url": "https://civicdb.org/links/evidence_items/1407", "evidence_direction": "Supports", "evidence_level": "B", "evidence_statement": "In the NCT00880321 trial using mutant BRAF inhibitor dabrafenib in solid tumors, 10 cases of melanoma brain metastases were assessed for dabrafenib response. In nine patients a decrease in size of metastases was seen, and in four cases a complete resolution of brain lesions was observed. This subset of patients had median progression free survival of 4.2 months.", "evidence_status": "accepted", "evidence_type": "Predictive", "gene": "BRAF", "gene_civic_url": null, "last_review_date": "2023-01-09 21:46:25 UTC", "nct_ids": [ "NCT00880321" ], "normalized_drug": [ "Dabrafenib" ], "phenotypes": [ "Brain neoplasm" ], "pub_med_references": [ 22608338 ], "rating": "4", "representative_transcript": null, "transcripts": null, "variant": "V600", "variant_civic_url": null, "variant_origin": "Somatic", "variant_summary": null, "gene_description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer. Oncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors. Class 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors. Class 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors. Class 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase." }, { "asco_entry": null, "clinical_significance": "Sensitivity/Response", "disease": "Skin Melanoma", "doid": "8923", "drug_interaction_type": null, "drugs": [ "Trametinib", "Dabrafenib" ], "entrez_id": null, "evidence_civic_url": "https://civicdb.org/links/evidence_items/1411", "evidence_direction": "Supports", "evidence_level": "A", "evidence_statement": "The Combi-v (NCT01597908) open-label, randomized phase 3 trial had 704 patients with metastatic melanoma with a BRAF V600 mutation. Patients were randomized to receive either a combination of dabrafenib and trametinib or vemurafenib orally as first-line therapy. At preplanned interim analysis the overall survival rate at 12 months was 72% (95% confidence interval [CI], 67 to 77) in the combination-therapy group and 65% (95% CI, 59 to 70) in the vemurafenib group (hazard ratio for death in the combination-therapy group, 0.69; 95% CI, 0.53 to 0.89; P=0.005). Median progression-free survival was 11.4 months in the combination-therapy group and 7.3 months in the vemurafenib group (hazard ratio, 0.56; 95% CI, 0.46 to 0.69; P<0.001). Cutaneous squamous-cell carcinoma and keratoacanthoma occurred at 1% with combination-therapy and 18% in the vemurafenib group.", "evidence_status": "accepted", "evidence_type": "Predictive", "gene": "BRAF", "gene_civic_url": null, "last_review_date": "2023-01-09 21:46:25 UTC", "nct_ids": [ "NCT01597908" ], "normalized_drug": [ "Dabrafenib, Trametinib" ], "phenotypes": null, "pub_med_references": [ 25399551 ], "rating": "5", "representative_transcript": null, "transcripts": null, "variant": "V600", "variant_civic_url": null, "variant_origin": "Somatic", "variant_summary": null, "gene_description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer. Oncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors. Class 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors. Class 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors. Class 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase." }, { "asco_entry": null, "clinical_significance": "Sensitivity/Response", "disease": "Colorectal Cancer", "doid": "9256", "drug_interaction_type": null, "drugs": [ "Dabrafenib", "Trametinib" ], "entrez_id": null, "evidence_civic_url": "https://civicdb.org/links/evidence_items/1415", "evidence_direction": "Supports", "evidence_level": "B", "evidence_statement": "In clinical trial NCT01072175, 43 patients with BRAF V600 metastatic colorectal cancer (CRC) received mutant BRAF inhibitor dabrafenib and MEK inhibitor trametinib. Only 12% of patients showed partial response or better, with one complete response lasting 36 months and ongoing after data cutoff. 56% of patients achieved stable disease. The median progression free survival (PFS) was 3.5 months, longer than the median PFS (2.5 months) reported for metastatic CRC treated with standard chemotherapy. The authors conclude that MAPK targeting in CRC is a valid approach that can produce meaningful responses but additional work is required to more effectively inhibit the pathway.", "evidence_status": "accepted", "evidence_type": "Predictive", "gene": "BRAF", "gene_civic_url": null, "last_review_date": "2023-01-09 21:46:25 UTC", "nct_ids": [ "NCT01072175" ], "normalized_drug": [ "Dabrafenib, Trametinib" ], "phenotypes": null, "pub_med_references": [ 26392102 ], "rating": "2", "representative_transcript": null, "transcripts": null, "variant": "V600", "variant_civic_url": null, "variant_origin": "Somatic", "variant_summary": null, "gene_description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer. Oncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors. Class 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors. Class 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors. Class 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase." }, { "asco_entry": null, "clinical_significance": "Resistance", "disease": "Skin Melanoma", "doid": "8923", "drug_interaction_type": null, "drugs": [ "Vemurafenib" ], "entrez_id": null, "evidence_civic_url": "https://civicdb.org/links/evidence_items/1416", "evidence_direction": "Supports", "evidence_level": "D", "evidence_statement": "Foundation One NGS assay and targeted RNAseq identified PAPSS1-BRAF fusion in a melanoma sample. Further BRAF fusions (TRIM24-BRAF) were identified in TCGA and additional samples. Ectopic expression of engineered cDNA in 293H cells showed that trametinib led to reduced ERK1/2 phosphorylation in fusion positive cells whereas vemurafenib was not effective.", "evidence_status": "accepted", "evidence_type": "Predictive", "gene": "BRAF", "gene_civic_url": null, "last_review_date": "2023-01-09 21:46:31 UTC", "nct_ids": null, "normalized_drug": [ "Vemurafenib" ], "phenotypes": null, "pub_med_references": [ 24345920 ], "rating": "3", "representative_transcript": null, "transcripts": null, "variant": "TRIM24::BRAF", "variant_civic_url": null, "variant_origin": "Somatic", "variant_summary": null, "gene_description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer. Oncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors. Class 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors. Class 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors. Class 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase." }, { "asco_entry": null, "clinical_significance": "Sensitivity/Response", "disease": "Melanoma", "doid": "1909", "drug_interaction_type": null, "drugs": [ "Vemurafenib", "Cobimetinib" ], "entrez_id": null, "evidence_civic_url": "https://civicdb.org/links/evidence_items/1422", "evidence_direction": "Supports", "evidence_level": "B", "evidence_statement": "In a randomized phase 3 study, previously untreated advanced or metastatic BRAF V600 mutation-positive melanoma patients treated with combination vemurafenib and cobimetinib showed improved progression free survival (9.9 vs 6.2 months), increased rate of complete or partial response (68% vs 45%), and improved overall survival at 9 months ( 81% vs 73%) compared to the vemurafenib and placebo control group.", "evidence_status": "accepted", "evidence_type": "Predictive", "gene": "BRAF", "gene_civic_url": null, "last_review_date": "2023-01-09 21:46:25 UTC", "nct_ids": [ "NCT01689519" ], "normalized_drug": [ "Cobimetinib, Vemurafenib" ], "phenotypes": null, "pub_med_references": [ 25265494 ], "rating": "4", "representative_transcript": null, "transcripts": null, "variant": "V600", "variant_civic_url": null, "variant_origin": "Somatic", "variant_summary": null, "gene_description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer. Oncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors. Class 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors. Class 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors. Class 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase." }, { "asco_entry": null, "clinical_significance": "Sensitivity/Response", "disease": "Skin Melanoma", "doid": "8923", "drug_interaction_type": null, "drugs": [ "Trametinib" ], "entrez_id": null, "evidence_civic_url": "https://civicdb.org/links/evidence_items/1570", "evidence_direction": "Supports", "evidence_level": "C", "evidence_statement": "Case report of a 47year old female patient with metastatic melanoma (BRAF, NRAS, KIT negative). A PPFIBP2-BRAF fusion was identified from DNA from a brain metastasis (inton 3 of PPFIBP2 fused to intron 10 of BRAF). Trametinib was introduced and anemia and ECOG status improved. Imaging revealed a 90% decrease in extracranial and 19% decrease in intracranial metastases with no new metastases and no progressing sites at 6 weeks. Trametinib was stopped and pembrolizumab introduced at this time. Progressive disease was noted after 5 cycles of pembrolizumab but re-introduction of trametinib did not show an effect.", "evidence_status": "accepted", "evidence_type": "Predictive", "gene": "BRAF", "gene_civic_url": null, "last_review_date": "2023-01-09 21:46:36 UTC", "nct_ids": null, "normalized_drug": [ "Trametinib" ], "phenotypes": null, "pub_med_references": [ 26072686 ], "rating": "2", "representative_transcript": null, "transcripts": null, "variant": "PPFIBP2::BRAF", "variant_civic_url": null, "variant_origin": "Somatic", "variant_summary": null, "gene_description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer. Oncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors. Class 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors. Class 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors. Class 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase." }, { "asco_entry": null, "clinical_significance": "Sensitivity/Response", "disease": "Skin Melanoma", "doid": "8923", "drug_interaction_type": null, "drugs": [ "Trametinib" ], "entrez_id": null, "evidence_civic_url": "https://civicdb.org/links/evidence_items/1571", "evidence_direction": "Supports", "evidence_level": "C", "evidence_statement": "A 65 yr old male patient with metastatic acral lentiginous melanoma (BRAF, NRAS, KIT negative) was found to harbor a KIAA1549-BRAF (intron 15-intron 8) fusion in a subcutaneous metastasis sample after disease progression. Trametinib was started and fatigue and ECOG status improved but imaging revealed slight disease progression after 2 weeks (15 sites measurable, 9 stable, 6 progressive). No new metastases were identified. The patient was switched to pembrolizumab and major disease progression was noted.", "evidence_status": "accepted", "evidence_type": "Predictive", "gene": "BRAF", "gene_civic_url": null, "last_review_date": "2023-01-09 21:46:36 UTC", "nct_ids": null, "normalized_drug": [ "Trametinib" ], "phenotypes": null, "pub_med_references": [ 26072686 ], "rating": "1", "representative_transcript": null, "transcripts": null, "variant": "KIAA1549::BRAF", "variant_civic_url": null, "variant_origin": "Somatic", "variant_summary": null, "gene_description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer. Oncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors. Class 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors. Class 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors. Class 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase." }, { "asco_entry": null, "clinical_significance": "Sensitivity/Response", "disease": "Lung Non-small Cell Carcinoma", "doid": "3908", "drug_interaction_type": null, "drugs": [ "Vemurafenib" ], "entrez_id": null, "evidence_civic_url": "https://civicdb.org/links/evidence_items/1574", "evidence_direction": "Supports", "evidence_level": "B", "evidence_statement": "Patients with BRAF-V600 mutated cancers were identified (n=122) and clinical response to vemurafenib was evaluated. Of the 20 patients with non-small-cell-lung cancer (17 with BRAF V600E, one with BRAF V600G and one with BRAF V600 unknown status), 19 were evaluable and the response rate to vemurafenib was 42%, tumor regression was observed in 14/19 patients, progression-free survival was 7.3 months, and 12-month overall survival was 66%.", "evidence_status": "accepted", "evidence_type": "Predictive", "gene": "BRAF", "gene_civic_url": null, "last_review_date": "2023-01-09 21:46:25 UTC", "nct_ids": [ "NCT01524978" ], "normalized_drug": [ "Vemurafenib" ], "phenotypes": null, "pub_med_references": [ 26287849 ], "rating": "3", "representative_transcript": null, "transcripts": null, "variant": "V600", "variant_civic_url": null, "variant_origin": "Somatic", "variant_summary": null, "gene_description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer. Oncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors. Class 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors. Class 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors. Class 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase." }, { "asco_entry": null, "clinical_significance": "Sensitivity/Response", "disease": "Langerhans-cell Histiocytosis", "doid": "2571", "drug_interaction_type": null, "drugs": [ "Vemurafenib" ], "entrez_id": null, "evidence_civic_url": "https://civicdb.org/links/evidence_items/1575", "evidence_direction": "Supports", "evidence_level": "B", "evidence_statement": "Patients with BRAF-V600 mutated cancers were identified (n=122) and clinical response to vemurafenib was evaluated. Of the 14 patients with Langerhans’-cell histiocytosis, 43% of patients had a response to vemurafenib (1 complete and 5 partial responses), disease regression was observed in 12/14 patients, all patients detailed improvement in disease-related symptoms, 0 patients had progressive disease during treatment, 12-month progression free survival was 91%, and overall survival rate was 100%. Among all 18 patients with Erdheim-Chester disease or Langerhans histiocytosis, 94% had BRAF V600E mutations and the remaining 6 percent (1 patient) had an unknown V600 mutation.", "evidence_status": "accepted", "evidence_type": "Predictive", "gene": "BRAF", "gene_civic_url": null, "last_review_date": "2023-01-09 21:46:25 UTC", "nct_ids": [ "NCT01524978" ], "normalized_drug": [ "Vemurafenib" ], "phenotypes": null, "pub_med_references": [ 26287849 ], "rating": "3", "representative_transcript": null, "transcripts": null, "variant": "V600", "variant_civic_url": null, "variant_origin": "Somatic", "variant_summary": null, "gene_description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer. Oncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors. Class 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors. Class 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors. Class 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase." }, { "asco_entry": null, "clinical_significance": "Resistance", "disease": "Colorectal Cancer", "doid": "9256", "drug_interaction_type": null, "drugs": [ "Vemurafenib" ], "entrez_id": null, "evidence_civic_url": "https://civicdb.org/links/evidence_items/1576", "evidence_direction": "Supports", "evidence_level": "B", "evidence_statement": "Patients with BRAF-V600 mutated cancers were identified (n=122) and clinical response to vemurafenib was evaluated. Of the 10 patients with colorectal cancer (80% BRAF V600E, 20% V600 unknown status), no responses were observed and overall survival was 9.3 months with a median progression-free survival of 4.5 months.", "evidence_status": "accepted", "evidence_type": "Predictive", "gene": "BRAF", "gene_civic_url": null, "last_review_date": "2023-01-09 21:46:25 UTC", "nct_ids": [ "NCT01524978" ], "normalized_drug": [ "Vemurafenib" ], "phenotypes": null, "pub_med_references": [ 26287849 ], "rating": "3", "representative_transcript": null, "transcripts": null, "variant": "V600", "variant_civic_url": null, "variant_origin": "Somatic", "variant_summary": null, "gene_description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer. Oncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors. Class 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors. Class 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors. Class 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase." }, { "asco_entry": null, "clinical_significance": "Sensitivity/Response", "disease": "Colorectal Cancer", "doid": "9256", "drug_interaction_type": null, "drugs": [ "Vemurafenib", "Cetuximab" ], "entrez_id": null, "evidence_civic_url": "https://civicdb.org/links/evidence_items/1598", "evidence_direction": "Does Not Support", "evidence_level": "B", "evidence_statement": "Patients with BRAF-V600 mutated cancers were identified (n=122) and subsequently underwent targeted therapy. 27 patients with colorectal cancer were treated with vemurafenib and cetuximab (N=24 with BRAF V600E mutation, N=3 with V600 unknown status). One response was observed; however, approximately half the patients had tumor regression that did not meet the standard criteria for a partial response. Median progression-free survival and overall survival for patients receiving combination therapy were 3.7 months (95% CI, 1.8 to 5.1) and 7.1 months (95% CI, 4.4 to not reached), respectively. Patients were heavily pretreated, with a median of two lines of previous therapy (range, one to six).", "evidence_status": "accepted", "evidence_type": "Predictive", "gene": "BRAF", "gene_civic_url": null, "last_review_date": "2023-01-09 21:46:25 UTC", "nct_ids": [ "NCT01524978" ], "normalized_drug": [ "Cetuximab", "Vemurafenib" ], "phenotypes": null, "pub_med_references": [ 26287849 ], "rating": "2", "representative_transcript": null, "transcripts": null, "variant": "V600", "variant_civic_url": null, "variant_origin": "Somatic", "variant_summary": null, "gene_description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer. Oncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors. Class 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors. Class 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors. Class 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase." }, { "asco_entry": null, "clinical_significance": "Sensitivity/Response", "disease": "Ovarian Serous Carcinoma", "doid": "0050933", "drug_interaction_type": null, "drugs": [ "Mitogen-Activated Protein Kinase Kinase Inhibitor" ], "entrez_id": null, "evidence_civic_url": "https://civicdb.org/links/evidence_items/1662", "evidence_direction": "Supports", "evidence_level": "C", "evidence_statement": "One patient with low-grade serous ovarian cancer had an in-frame fusion between the BRAF kinase domain and CUL1 identified by panel sequencing (MSK-IMPACT), with expression confirmed by whole-transcriptome sequencing. This patient with metastatic disease after treatment with carboplatin and paclitaxel, was enrolled onto a study of paclitaxel in combination with an oral MEK inhibitor and achieved a CR. She continued to receive therapy for 7 months, until discontinuation because of the development of pneumonitis. At publication, sustained CR had lasted > 18 months.", "evidence_status": "accepted", "evidence_type": "Predictive", "gene": "BRAF", "gene_civic_url": null, "last_review_date": "2023-01-09 21:46:37 UTC", "nct_ids": null, "normalized_drug": null, "phenotypes": null, "pub_med_references": [ 26324360 ], "rating": "2", "representative_transcript": null, "transcripts": null, "variant": "BRAF::CUL1", "variant_civic_url": null, "variant_origin": "Somatic", "variant_summary": null, "gene_description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer. Oncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors. Class 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors. Class 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors. Class 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase." }, { "asco_entry": null, "clinical_significance": "Sensitivity/Response", "disease": "Melanoma", "doid": "1909", "drug_interaction_type": null, "drugs": [ "Trametinib" ], "entrez_id": null, "evidence_civic_url": "https://civicdb.org/links/evidence_items/1663", "evidence_direction": "Supports", "evidence_level": "C", "evidence_statement": "Analysis of BRAF fusions in 20,573 tumors, across 12 distinct tumor types. BRAF fusions were identified in 55 (0.3%) patients and enriched in spitzoid melanoma, pilocytic astrocytomas, pancreatic acinar and papillary thyroid cancers. Clinical data were available for two patients. Among them one 46-year old woman with spitzoid melanoma that harbored a ZKSCAN1-BRAF fusion responded to treatment with the MEK inhibitor trametinib. Subcutaneous tumor nodules exhibited clinical responses within 14 days of therapy, and her dominant bulky right lung metastases showed significant response by Day 45. Subsequent robotic-assisted lobectomy was able to remove the previously unresectable tumor with clean surgical margins.", "evidence_status": "accepted", "evidence_type": "Predictive", "gene": "BRAF", "gene_civic_url": null, "last_review_date": "2023-01-09 21:46:37 UTC", "nct_ids": null, "normalized_drug": [ "Trametinib" ], "phenotypes": null, "pub_med_references": [ 26314551 ], "rating": "3", "representative_transcript": null, "transcripts": null, "variant": "ZKSCAN1::BRAF", "variant_civic_url": null, "variant_origin": "Somatic", "variant_summary": null, "gene_description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer. Oncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors. Class 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors. Class 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors. Class 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase." }, { "asco_entry": null, "clinical_significance": "Sensitivity/Response", "disease": "Spindle Cell Sarcoma", "doid": "4235", "drug_interaction_type": null, "drugs": [ "Bevacizumab", "Sorafenib", "Temsirolimus" ], "entrez_id": null, "evidence_civic_url": "https://civicdb.org/links/evidence_items/1664", "evidence_direction": "Supports", "evidence_level": "C", "evidence_statement": "A patient with a malignant spindle cell tumor of the chest wall treated as a soft tissue sarcoma was identified to harbor a KIAA1549-BRAF fusion. This patient responded to treatment with the pan-kinase inhibitor sorafenib in combination with bevacizumab and temsirolimus, achieving stable disease after 2 cycles extending into 11 cycles at which time she expired due to co-morbidities (acute myocardial infarction, hypotension). Of note, sequencing of 236 cancer-related genes identified CDKN2A A68fs*51, SUFU E283fs*3, MAP3K1 N325fs*3 and homozygous deletion of PTEN as well.", "evidence_status": "accepted", "evidence_type": "Predictive", "gene": "BRAF", "gene_civic_url": null, "last_review_date": "2023-01-09 21:46:36 UTC", "nct_ids": [ "NCT01187199" ], "normalized_drug": [ "Bevacizumab", "Sorafenib", "Temsirolimus" ], "phenotypes": null, "pub_med_references": [ 24422672 ], "rating": "2", "representative_transcript": null, "transcripts": null, "variant": "KIAA1549::BRAF", "variant_civic_url": null, "variant_origin": "Somatic", "variant_summary": null, "gene_description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer. Oncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors. Class 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors. Class 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors. Class 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase." }, { "asco_entry": null, "clinical_significance": "Resistance", "disease": "Colorectal Cancer", "doid": "9256", "drug_interaction_type": null, "drugs": [ "Cetuximab" ], "entrez_id": null, "evidence_civic_url": "https://civicdb.org/links/evidence_items/1704", "evidence_direction": "Supports", "evidence_level": "D", "evidence_statement": "A cohort of patient-derived xenografts (PDX) from 85 patients with metastatic colorectal cancer was created. PDX were treated with cetuximab and mechanisms of resistance investigated. None of the xenografts harboring KRAS (N=18), NRAS (N=7) or BRAF (N=3) mutations showed a response to cetuximab whereas 1 out of 4 xenografts with a PIK3CA mutation responded to cetuximab.", "evidence_status": "accepted", "evidence_type": "Predictive", "gene": "BRAF", "gene_civic_url": null, "last_review_date": "2023-01-09 21:46:33 UTC", "nct_ids": null, "normalized_drug": [ "Cetuximab" ], "phenotypes": null, "pub_med_references": [ 22586653 ], "rating": "2", "representative_transcript": null, "transcripts": null, "variant": "Mutation", "variant_civic_url": null, "variant_origin": "Somatic", "variant_summary": null, "gene_description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer. Oncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors. Class 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors. Class 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors. Class 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase." }, { "asco_entry": null, "clinical_significance": "Sensitivity/Response", "disease": "Melanoma", "doid": "1909", "drug_interaction_type": null, "drugs": [ "Trametinib" ], "entrez_id": null, "evidence_civic_url": "https://civicdb.org/links/evidence_items/1750", "evidence_direction": "Supports", "evidence_level": "B", "evidence_statement": "Patients who had histologically confirmed, unresectable stage IIIC or IV cutaneous melanoma with a V600E or V600K BRAF mutation were eligible for the study. 322 eligible patients (281 with the V600E mutation, 40 with the V600K mutation, and 1 with both mutations) in a 2:1 ratio to receive oral trametinib (2 mg once daily) or intravenous chemotherapy consisting of either dacarbazine (1000 mg per square meter of body-surface area) or paclitaxel (175 mg per square meter), at the discretion of the investigator, every 3 weeks. The primary end point was progression-free survival; secondary end points included overall survival, overall response rate, duration of response, and safety. Treatment continued until disease progression, death, or withdrawal from the study. In the intention-to-treat population, the median duration of progression-free survival was 4.8 months in the trametinib group as compared with 1.5 months in the chemotherapy group (hazard ratio for progression, 0.45; 95% confidence interval [CI], 0.33 to 0.63; P<0.001). The 6-month overall survival rate in the intention-to-treat population was 81% in the trametinib group and 67% in the chemotherapy group.", "evidence_status": "accepted", "evidence_type": "Predictive", "gene": "BRAF", "gene_civic_url": null, "last_review_date": "2023-01-09 21:46:25 UTC", "nct_ids": [ "NCT01245062" ], "normalized_drug": [ "Trametinib" ], "phenotypes": null, "pub_med_references": [ 22663011 ], "rating": "3", "representative_transcript": null, "transcripts": null, "variant": "V600", "variant_civic_url": null, "variant_origin": "Somatic", "variant_summary": null, "gene_description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer. Oncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors. Class 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors. Class 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors. Class 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase." }, { "asco_entry": null, "clinical_significance": "Resistance", "disease": "Colorectal Cancer", "doid": "9256", "drug_interaction_type": null, "drugs": [ "Chemotherapy", "Cetuximab" ], "entrez_id": null, "evidence_civic_url": "https://civicdb.org/links/evidence_items/2187", "evidence_direction": "Supports", "evidence_level": "B", "evidence_statement": "This was a retrospective study of 350 patients with metastatic, chemotherapy refractory colorectal cancer treated with cetuximab + chemotherapy who had individual response data and whose tumors were KRAS wildtype and BRAF assessable. Patients harboring BRAF mutations (total n=24, V600E n=23, D594G n=1) had a lower response rate than did patients with wildtype BRAF (n=326; 2/24 [4.3%] vs 124/326 [38%], OR: 0.15, p=0.0012). BRAF mutant patients also experienced significantly lower disease control rate, PFS, and OS (median 26 vs 54 weeks, HR: 3.03 p<0.0001) in response to cetuximab treatment. In multivariate analysis, the significant associations between BRAF mutations and poor outcome were confirmed. The authors noted that two responders had the following genotypes: V600E mutation in low copy number, and BRAF D594G, and suggested that mutation status of BRAF is more informative than those of NRAS and PIK3CA exon 20 for predicting cetuximab response (second only to KRAS).", "evidence_status": "accepted", "evidence_type": "Predictive", "gene": "BRAF", "gene_civic_url": null, "last_review_date": "2023-01-09 21:46:33 UTC", "nct_ids": null, "normalized_drug": [ "Cetuximab" ], "phenotypes": null, "pub_med_references": [ 20619739 ], "rating": "3", "representative_transcript": null, "transcripts": null, "variant": "Mutation", "variant_civic_url": null, "variant_origin": "Somatic", "variant_summary": null, "gene_description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer. Oncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors. Class 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors. Class 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors. Class 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase." }, { "asco_entry": null, "clinical_significance": "Resistance", "disease": "Colorectal Cancer", "doid": "9256", "drug_interaction_type": null, "drugs": [ "Panitumumab", "Dabrafenib" ], "entrez_id": null, "evidence_civic_url": "https://civicdb.org/links/evidence_items/2929", "evidence_direction": "Supports", "evidence_level": "C", "evidence_statement": "Paired pre-treatment and post-progression tumor biopsies from BRAF-mutant CRC patients treated with RAF inhibitor combinations were analyzed. Alterations in MAPK pathway genes were found in resistant tumors not present in matched pre-treatment tumors, including KRAS amplification, BRAF amplification, and a MEK1 mutation.", "evidence_status": "accepted", "evidence_type": "Predictive", "gene": "BRAF", "gene_civic_url": null, "last_review_date": "2023-01-09 21:46:44 UTC", "nct_ids": null, "normalized_drug": [ "Dabrafenib", "Panitumumab" ], "phenotypes": null, "pub_med_references": null, "rating": "3", "representative_transcript": null, "transcripts": null, "variant": "Amplification", "variant_civic_url": null, "variant_origin": "Somatic", "variant_summary": null, "gene_description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer. Oncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors. Class 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors. Class 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors. Class 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase." }, { "asco_entry": null, "clinical_significance": "Better Outcome", "disease": "Colorectal Cancer", "doid": "9256", "drug_interaction_type": null, "drugs": null, "entrez_id": null, "evidence_civic_url": "https://civicdb.org/links/evidence_items/3046", "evidence_direction": "Supports", "evidence_level": "B", "evidence_statement": "This study of 9,643 patients characterized clinical implications of non-V600 BRAF mutations in metastatic CRC. Of the patients with metastatic CRC that underwent NGS testing, 208 patients had non-V600 BRAF mutations (22% of BRAF mutations identified and 2.2% of total patients tested ). When compared to V600 BRAF mutations, tumors without V600 BRAF mutations were more prevalent in younger patients (58 v 68 years, respectively) and male patients (65% vs 46%, respectively). Additionally, non-V600 BRAF mutations were less prevalent in high-grade tumors (13% v 64%, respectively) and right-sided primary tumors (36% v 81%, respectively). Median overall survival was significantly longer in patients with non-V600 BRAF-mutant metastatic CRC compared with those with both V600E BRAF-mutant and wild-type BRAF metastatic CRC (60.7 v 11.4 v 43.0 months).", "evidence_status": "accepted", "evidence_type": "Prognostic", "gene": "BRAF", "gene_civic_url": null, "last_review_date": "2023-01-09 21:46:58 UTC", "nct_ids": null, "normalized_drug": null, "phenotypes": null, "pub_med_references": [ 28486044 ], "rating": "5", "representative_transcript": null, "transcripts": null, "variant": "Non-V600", "variant_civic_url": null, "variant_origin": "Somatic", "variant_summary": null, "gene_description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer. Oncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors. Class 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors. Class 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors. Class 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase." }, { "asco_entry": null, "clinical_significance": "Sensitivity/Response", "disease": "Gastrointestinal Stromal Tumor", "doid": "9253", "drug_interaction_type": null, "drugs": [ "Regorafenib" ], "entrez_id": null, "evidence_civic_url": "https://civicdb.org/links/evidence_items/4121", "evidence_direction": "Does Not Support", "evidence_level": "C", "evidence_statement": "This phase II clinical trial of regorafenib (NCT01068769) examined the long term safety and efficacy of regorafenib monotherapy in patients with metastatic and/or unresectable gastrointestinal stromal tumors (GISTs) who failed previous treatments with imatinib. One patient's GIST harbored a BRAF exon 15 mutation.This patient experienced progressive disease and a progression free survival of 1.6 months.", "evidence_status": "accepted", "evidence_type": "Predictive", "gene": "BRAF", "gene_civic_url": null, "last_review_date": "2023-01-09 21:47:01 UTC", "nct_ids": [ "NCT01068769" ], "normalized_drug": [ "Regorafenib" ], "phenotypes": null, "pub_med_references": [ 27371698 ], "rating": "2", "representative_transcript": null, "transcripts": null, "variant": "Exon 15 Mutation", "variant_civic_url": null, "variant_origin": "Somatic", "variant_summary": null, "gene_description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer. Oncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors. Class 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors. Class 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors. Class 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase." }, { "asco_entry": null, "clinical_significance": "Resistance", "disease": "Gastrointestinal Stromal Tumor", "doid": "9253", "drug_interaction_type": null, "drugs": [ "Regorafenib" ], "entrez_id": null, "evidence_civic_url": "https://civicdb.org/links/evidence_items/4605", "evidence_direction": "Supports", "evidence_level": "C", "evidence_statement": "This retrospective study of a phase 2 clinical trial (NCT01068769) examined regorafenib safety and efficacy in advanced gastrointestinal stromal tumor (GIST) patients refractory to at least imatinib and sunitinib. One patient whose GIST harbored a BRAF exon 15 mutation and wildtype KIT and PDGFRA experienced rapid disease progression despite regorafenib administration.", "evidence_status": "accepted", "evidence_type": "Predictive", "gene": "BRAF", "gene_civic_url": null, "last_review_date": "2023-01-09 21:47:01 UTC", "nct_ids": null, "normalized_drug": [ "Regorafenib" ], "phenotypes": null, "pub_med_references": [ 22614970 ], "rating": "1", "representative_transcript": null, "transcripts": null, "variant": "Exon 15 Mutation", "variant_civic_url": null, "variant_origin": "Somatic", "variant_summary": null, "gene_description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer. Oncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors. Class 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors. Class 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors. Class 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase." }, { "asco_entry": null, "clinical_significance": "Sensitivity/Response", "disease": "Cholangiocarcinoma", "doid": "4947", "drug_interaction_type": null, "drugs": [ "Vemurafenib" ], "entrez_id": null, "evidence_civic_url": "https://civicdb.org/links/evidence_items/5905", "evidence_direction": "Supports", "evidence_level": "B", "evidence_statement": "Eight patients with BRAF V600 (7 with V600E, 1 with V600 unknown) mutated cholangiocarcinoma received vemurafenib. Only one patients showed partial response and duration of response of this patient was longer than 12 months.", "evidence_status": "accepted", "evidence_type": "Predictive", "gene": "BRAF", "gene_civic_url": null, "last_review_date": "2023-01-09 21:46:25 UTC", "nct_ids": [ "NCT01524978" ], "normalized_drug": [ "Vemurafenib" ], "phenotypes": null, "pub_med_references": [ 26287849 ], "rating": "4", "representative_transcript": null, "transcripts": null, "variant": "V600", "variant_civic_url": null, "variant_origin": "Somatic", "variant_summary": null, "gene_description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer. Oncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors. Class 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors. Class 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors. Class 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase." }, { "asco_entry": null, "clinical_significance": "Sensitivity/Response", "disease": "Cancer", "doid": "162", "drug_interaction_type": null, "drugs": [ "Vemurafenib" ], "entrez_id": null, "evidence_civic_url": "https://civicdb.org/links/evidence_items/5973", "evidence_direction": "Does Not Support", "evidence_level": "C", "evidence_statement": "The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patients with BRAF V600E mutations, objective responses were seen in 12 patients (46%; 95% CI, 27% to 67%). Only one of 23 patients (4%; 95% CI, 0% to 22%) with other non-V600 BRAF mutations had a PR (pancreas cancer with a CUX1-BRAF fusion). Nonresponding BRAF mutations included: K601E (n = 6), G464V (n = 2), G469A (n = 2), G496A (n = 2), N581S (n = 2), and one each for G466V, G596R, G606E, L597Q, P731T, intron 9 rearrangement, intron 10 rearrangement, and MACF1- and WASFL-BRAF fusion.", "evidence_status": "accepted", "evidence_type": "Predictive", "gene": "BRAF", "gene_civic_url": null, "last_review_date": "2023-01-09 21:46:57 UTC", "nct_ids": [ "NCT02091141" ], "normalized_drug": [ "Vemurafenib" ], "phenotypes": null, "pub_med_references": null, "rating": "2", "representative_transcript": null, "transcripts": null, "variant": "intron 9 rearrangement", "variant_civic_url": null, "variant_origin": "Somatic", "variant_summary": null, "gene_description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer. Oncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors. Class 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors. Class 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors. Class 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase." }, { "asco_entry": null, "clinical_significance": "Sensitivity/Response", "disease": "Cancer", "doid": "162", "drug_interaction_type": null, "drugs": [ "Vemurafenib" ], "entrez_id": null, "evidence_civic_url": "https://civicdb.org/links/evidence_items/5974", "evidence_direction": "Does Not Support", "evidence_level": "C", "evidence_statement": "The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively Of 26 patients with BRAF V600E mutations, objective responses were seen in 12 patients (46%; 95% CI, 27% to 67%). Only one of 23 patients (4%; 95% CI, 0% to 22%) with other non-V600 BRAF mutations had a PR (pancreas cancer with a CUX1-BRAF fusion). Nonresponding BRAF mutations included: K601E (n = 6), G464V (n = 2), G469A (n = 2), G496A (n = 2), N581S (n = 2), and one each for G466V, G596R, G606E, L597Q, P731T, intron 9 rearrangement, intron 10 rearrangement, and MACF1- and WASFL-BRAF fusion.", "evidence_status": "accepted", "evidence_type": "Predictive", "gene": "BRAF", "gene_civic_url": null, "last_review_date": "2023-01-09 21:46:57 UTC", "nct_ids": [ "NCT02091141" ], "normalized_drug": [ "Vemurafenib" ], "phenotypes": null, "pub_med_references": null, "rating": "2", "representative_transcript": null, "transcripts": null, "variant": "intron 10 rearrangement", "variant_civic_url": null, "variant_origin": "Somatic", "variant_summary": null, "gene_description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer. Oncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors. Class 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors. Class 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors. Class 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase." }, { "asco_entry": null, "clinical_significance": "Sensitivity/Response", "disease": "Cancer", "doid": "162", "drug_interaction_type": null, "drugs": [ "Vemurafenib" ], "entrez_id": null, "evidence_civic_url": "https://civicdb.org/links/evidence_items/5975", "evidence_direction": "Does Not Support", "evidence_level": "C", "evidence_statement": "The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively Of 26 patients with BRAF V600E mutations, objective responses were seen in 12 patients (46%; 95% CI, 27% to 67%). Only one of 23 patients (4%; 95% CI, 0% to 22%) with other non-V600 BRAF mutations had a PR (pancreas cancer with a CUX1-BRAF fusion). Nonresponding BRAF mutations included: K601E (n = 6), G464V (n = 2), G469A (n = 2), G496A (n = 2), N581S (n = 2), and one each for G466V, G596R, G606E, L597Q, P731T, intron 9 rearrangement, intron 10 rearrangement, and MACF1- and WASFL-BRAF fusion.", "evidence_status": "accepted", "evidence_type": "Predictive", "gene": "BRAF", "gene_civic_url": null, "last_review_date": "2023-01-09 21:46:57 UTC", "nct_ids": [ "NCT02091141" ], "normalized_drug": [ "Vemurafenib" ], "phenotypes": null, "pub_med_references": null, "rating": "2", "representative_transcript": null, "transcripts": null, "variant": "MACF1::BRAF", "variant_civic_url": null, "variant_origin": "Somatic", "variant_summary": null, "gene_description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer. Oncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors. Class 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors. Class 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors. Class 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase." }, { "asco_entry": null, "clinical_significance": "Sensitivity/Response", "disease": "Cancer", "doid": "162", "drug_interaction_type": null, "drugs": [ "Vemurafenib" ], "entrez_id": null, "evidence_civic_url": "https://civicdb.org/links/evidence_items/5976", "evidence_direction": "Does Not Support", "evidence_level": "C", "evidence_statement": "The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patients with BRAF V600E mutations, objective responses were seen in 12 patients (46%; 95% CI, 27% to 67%). Only one of 23 patients (4%; 95% CI, 0% to 22%) with other non-V600 BRAF mutations had a PR (pancreas cancer with a CUX1-BRAF fusion). Nonresponding BRAF mutations included: K601E (n = 6), G464V (n = 2), G469A (n = 2), G496A (n = 2), N581S (n = 2), and one each for G466V, G596R, G606E, L597Q, P731T, intron 9 rearrangement, intron 10 rearrangement, and MACF1- and WASFL-BRAF fusion.", "evidence_status": "accepted", "evidence_type": "Predictive", "gene": "BRAF", "gene_civic_url": null, "last_review_date": "2023-01-09 21:46:57 UTC", "nct_ids": [ "NCT02091141" ], "normalized_drug": [ "Vemurafenib" ], "phenotypes": null, "pub_med_references": null, "rating": "2", "representative_transcript": null, "transcripts": null, "variant": "WASFL::BRAF", "variant_civic_url": null, "variant_origin": "Somatic", "variant_summary": null, "gene_description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer. Oncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors. Class 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors. Class 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors. Class 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase." }, { "asco_entry": null, "clinical_significance": "Sensitivity/Response", "disease": "Pancreatic Cancer", "doid": "1793", "drug_interaction_type": null, "drugs": [ "Vemurafenib" ], "entrez_id": null, "evidence_civic_url": "https://civicdb.org/links/evidence_items/5977", "evidence_direction": "Supports", "evidence_level": "C", "evidence_statement": "The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. One of 23 patients (4%; 95% CI, 0% to 22%) with other non-V600 BRAF mutations had a PR (pancreas cancer with a CUX1-BRAF fusion).", "evidence_status": "accepted", "evidence_type": "Predictive", "gene": "BRAF", "gene_civic_url": null, "last_review_date": "2023-01-09 21:46:57 UTC", "nct_ids": [ "NCT02091141" ], "normalized_drug": [ "Vemurafenib" ], "phenotypes": null, "pub_med_references": null, "rating": "2", "representative_transcript": null, "transcripts": null, "variant": "CUX1::BRAF", "variant_civic_url": null, "variant_origin": "Somatic", "variant_summary": null, "gene_description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer. Oncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors. Class 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors. Class 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors. Class 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase." }, { "asco_entry": null, "clinical_significance": "Sensitivity/Response", "disease": "Melanoma", "doid": "1909", "drug_interaction_type": null, "drugs": [ "Cobimetinib", "Vemurafenib" ], "entrez_id": null, "evidence_civic_url": "https://civicdb.org/links/evidence_items/6044", "evidence_direction": "Supports", "evidence_level": "A", "evidence_statement": "In this double-blind, randomized, placebo-controlled, multicentre study, adult patients with histologically confirmed BRAF(V600) mutation-positive unresectable stage IIIC or stage IV melanoma were randomly assigned (1:1) to receive cobimetinib or placebo, in combination with oral vemurafenib. Progression-free survival was the primary endpoint. Between Jan 8, 2013, and Jan 31, 2014, 495 eligible adult patients were enrolled and randomly assigned to the cobimetinib plus vemurafenib group (n=247) or placebo plus vemurafenib group (n=248). Investigator-assessed median progression-free survival was 12.3 months for cobimetinib and vemurafenib versus 7.2 months for placebo and vemurafenib (HR 0.58 [95% CI 0.46-0.72], p<0.0001). Median overall survival was 22.3 months for cobimetinib and vemurafenib versus 17.4 months for placebo and vemurafenib (HR 0.70, 95% CI 0.55-0.90; p=0.005). The safety profile for cobimetinib and vemurafenib was tolerable and manageable, and no new safety signals were observed with longer follow-up.", "evidence_status": "accepted", "evidence_type": "Predictive", "gene": "BRAF", "gene_civic_url": null, "last_review_date": "2023-01-09 21:46:25 UTC", "nct_ids": [ "NCT01689519" ], "normalized_drug": [ "Cobimetinib, Vemurafenib" ], "phenotypes": null, "pub_med_references": [ 27480103 ], "rating": "5", "representative_transcript": null, "transcripts": null, "variant": "V600", "variant_civic_url": null, "variant_origin": "Somatic", "variant_summary": null, "gene_description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer. Oncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors. Class 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors. Class 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors. Class 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase." }, { "asco_entry": null, "clinical_significance": "Sensitivity/Response", "disease": "Colorectal Cancer", "doid": "9256", "drug_interaction_type": null, "drugs": [ "Cetuximab", "Encorafenib" ], "entrez_id": null, "evidence_civic_url": "https://civicdb.org/links/evidence_items/6046", "evidence_direction": "Supports", "evidence_level": "B", "evidence_statement": "In a Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab, Twenty-six patients with refractory BRAF V600 mutant metastatic CRC (mCRC) were treated with a selective RAF kinase inhibitor (encorafenib) plus a monoclonal antibody targeting EGFR (cetuximab). Confirmed overall response rates of 19% were observed and median progression-free survival was 3.7 months.", "evidence_status": "accepted", "evidence_type": "Predictive", "gene": "BRAF", "gene_civic_url": null, "last_review_date": "2023-01-09 21:46:25 UTC", "nct_ids": null, "normalized_drug": [ "Cetuximab, Encorafenib" ], "phenotypes": null, "pub_med_references": [ 28363909 ], "rating": "4", "representative_transcript": null, "transcripts": null, "variant": "V600", "variant_civic_url": null, "variant_origin": "Somatic", "variant_summary": null, "gene_description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer. Oncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors. Class 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors. Class 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors. Class 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase." }, { "asco_entry": null, "clinical_significance": "Sensitivity/Response", "disease": "Colorectal Cancer", "doid": "9256", "drug_interaction_type": null, "drugs": [ "Encorafenib", "Alpelisib", "Cetuximab" ], "entrez_id": null, "evidence_civic_url": "https://civicdb.org/links/evidence_items/6047", "evidence_direction": "Supports", "evidence_level": "B", "evidence_statement": "In a phase Ib dose-escalation study of encorafenib, cetuximab and alpelisib, twenty-eight patients with refractory BRAF V600-mutant metastatic CRC (mCRC) were treated with a selective RAF kinase inhibitor (encorafenib) plus a monoclonal antibody targeting EGFR (cetuximab) with a PI3Kα inhibitor (alpelisib). Confirmed overall response rates of 18% were observed and median progression-free survival was 4.2 months", "evidence_status": "accepted", "evidence_type": "Predictive", "gene": "BRAF", "gene_civic_url": null, "last_review_date": "2023-01-09 21:46:25 UTC", "nct_ids": null, "normalized_drug": [ "Alpelisib", "Cetuximab", "Encorafenib" ], "phenotypes": null, "pub_med_references": [ 28363909 ], "rating": "3", "representative_transcript": null, "transcripts": null, "variant": "V600", "variant_civic_url": null, "variant_origin": "Somatic", "variant_summary": null, "gene_description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer. Oncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors. Class 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors. Class 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors. Class 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase." }, { "asco_entry": null, "clinical_significance": "Sensitivity/Response", "disease": "Melanoma", "doid": "1909", "drug_interaction_type": null, "drugs": [ "Dabrafenib", "Trametinib" ], "entrez_id": null, "evidence_civic_url": "https://civicdb.org/links/evidence_items/6180", "evidence_direction": "Supports", "evidence_level": "B", "evidence_statement": "Combination Dabrafenib and Trametinib treatment was assessed for adjuvant treatment of stage III resected BRAF V600 mutant melanoma in the COMBI-AD trial NCT01682083. Patients were treated with combination therapy or placebo for 12 months. The estimated 3-year rate of relapse-free survival was 58% in the treated group and 39% in the placebo group with hazard ratio for relapse or death of 0.47 (95% CI, 0.39 to 0.58; P<0.001). 3-year overall survival rate for treated group was 86%, and 77% in the placebo group (hazard ratio for death, 0.57; 95% CI, 0.42-0.79; P=0.0006). The level of improvement observed did not cross the prespecified interim analysis boundary of P=0.000019. Distant metastasis-free survival and freedom from relapse was higher in the combination-treated group.", "evidence_status": "accepted", "evidence_type": "Predictive", "gene": "BRAF", "gene_civic_url": null, "last_review_date": "2023-01-09 21:46:25 UTC", "nct_ids": [ "NCT01682083" ], "normalized_drug": [ "Dabrafenib, Trametinib" ], "phenotypes": null, "pub_med_references": [ 28891408 ], "rating": "5", "representative_transcript": null, "transcripts": null, "variant": "V600", "variant_civic_url": null, "variant_origin": "Somatic", "variant_summary": null, "gene_description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer. Oncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors. Class 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors. Class 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors. Class 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase." }, { "asco_entry": null, "clinical_significance": "Poor Outcome", "disease": "Colorectal Cancer", "doid": "9256", "drug_interaction_type": null, "drugs": null, "entrez_id": null, "evidence_civic_url": "https://civicdb.org/links/evidence_items/6302", "evidence_direction": "Supports", "evidence_level": "B", "evidence_statement": "This was a retrospective clinical study of 168 metastatic colorectal cancer patients who received first line chemotherapy (made up of 5-fluorouracil (5-FU) only, 5-FU + oxaliplatin, 5-FU + irinotecan, or 5-FU + oxaliplatin + irinotecan) alone or with monoclonal antibodies (bevacizumab or cetuximab). It assessed the relationship between BRAF mutation status in primary tumors and post treatment PFS. Of 168 patients, 155 had wildtype BRAF and 13 had mutations in BRAF—including V600E and D594K. The study found that patients harboring a BRAF mutation had a significantly worse outcome than patients expressing wildtype BRAF, regardless of first line chemotherapy regimen or use of monoclonal antibody treatment (Median PFS: 4.3 and 12.5 months, respectively; p <.0001).", "evidence_status": "accepted", "evidence_type": "Prognostic", "gene": "BRAF", "gene_civic_url": null, "last_review_date": "2023-02-03 00:05:19 UTC", "nct_ids": null, "normalized_drug": null, "phenotypes": null, "pub_med_references": [ 19603024 ], "rating": "3", "representative_transcript": null, "transcripts": null, "variant": "Mutation", "variant_civic_url": null, "variant_origin": "Somatic", "variant_summary": null, "gene_description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer. Oncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors. Class 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors. Class 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors. Class 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase." }, { "asco_entry": null, "clinical_significance": "Resistance", "disease": "Colorectal Cancer", "doid": "9256", "drug_interaction_type": null, "drugs": [ "Oxaliplatin" ], "entrez_id": null, "evidence_civic_url": "https://civicdb.org/links/evidence_items/6303", "evidence_direction": "Supports", "evidence_level": "B", "evidence_statement": "This was a retrospective clinical study of 100 metastatic colorectal cancer patients who received FOLFOX (oxaliplatin + 5-fluorouracil + folinic acid) first-line therapy alone or with monoclonal antibodies (bevacizumab or cetuximab). It assessed the relationship between BRAF mutation status in primary tumors and response to oxaliplatin-based first-line therapy, as measured by post treatment PFS. Of 100 patients, 94 had wildtype BRAF and 6 had mutations in BRAF—including V600E and D594K. The study found that patients harboring a BRAF mutation were significantly more resistant to oxaliplatin-based first-line therapy than patients with wildtype BRAF (Median PFS: 5.0 and 11. 7 months, respectively; p < .0001).", "evidence_status": "accepted", "evidence_type": "Predictive", "gene": "BRAF", "gene_civic_url": null, "last_review_date": "2023-01-09 21:46:33 UTC", "nct_ids": null, "normalized_drug": [ "Oxaliplatin" ], "phenotypes": null, "pub_med_references": [ 19603024 ], "rating": "3", "representative_transcript": null, "transcripts": null, "variant": "Mutation", "variant_civic_url": null, "variant_origin": "Somatic", "variant_summary": null, "gene_description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer. Oncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors. Class 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors. Class 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors. Class 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase." }, { "asco_entry": null, "clinical_significance": "Resistance", "disease": "Colorectal Cancer", "doid": "9256", "drug_interaction_type": null, "drugs": [ "Irinotecan" ], "entrez_id": null, "evidence_civic_url": "https://civicdb.org/links/evidence_items/6304", "evidence_direction": "Supports", "evidence_level": "B", "evidence_statement": "This was a retrospective clinical study of 44 metastatic colorectal cancer patients who received FOLFIRI (5-Fluorouacil + Folinic acid + irinotecan) first-line therapy alone or with bevacizumab. It assessed the relationship between BRAF mutation status in primary tumors and response to irinotecan-based first line therapy, as measured by PFS. Of the 44 patients, 39 had wildtype BRAF and 5 had mutations in BRAF—including V600E and D594K. The study found that patients harboring a BRAF mutation were significantly more resistant to irinotecan-based first-line therapy than patients with wildtype BRAF (Median PFS: 3.5 and 12.8 months, respectively; p = .006).", "evidence_status": "accepted", "evidence_type": "Predictive", "gene": "BRAF", "gene_civic_url": null, "last_review_date": "2023-01-09 21:46:33 UTC", "nct_ids": null, "normalized_drug": [ "Irinotecan" ], "phenotypes": null, "pub_med_references": [ 19603024 ], "rating": "3", "representative_transcript": null, "transcripts": null, "variant": "Mutation", "variant_civic_url": null, "variant_origin": "Somatic", "variant_summary": null, "gene_description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer. Oncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors. Class 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors. Class 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors. Class 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase." }, { "asco_entry": null, "clinical_significance": "Resistance", "disease": "Colorectal Cancer", "doid": "9256", "drug_interaction_type": null, "drugs": [ "Bevacizumab" ], "entrez_id": null, "evidence_civic_url": "https://civicdb.org/links/evidence_items/6305", "evidence_direction": "Supports", "evidence_level": "B", "evidence_statement": "This was a retrospective clinical study of 97 metastatic colorectal cancer patients who received bevacizumab in conjunction with first-line chemotherapy (composed of 5-fluorouracil (5-FU) only, 5-FU + oxaliplatin, 5-FU + irinotecan, or 5-FU + oxaliplatin + irinotecan). It assessed the relationship between BRAF mutation status in primary tumors and response to bevacizumab-containing first line chemotherapy, as measured by PFS. Of the 97 patients,89 had wildtype BRAF and 8 had mutations in BRAF—including V600E and D594K. The study found that patients harboring a BRAF mutation were significantly more resistant to bevacizumab-containing first-line chemotherapy than patients with wildtype BRAF (Median PFS: 4.2 and 12.5 months, respectively; p < .0001).", "evidence_status": "accepted", "evidence_type": "Predictive", "gene": "BRAF", "gene_civic_url": null, "last_review_date": "2023-01-09 21:46:33 UTC", "nct_ids": null, "normalized_drug": [ "Bevacizumab" ], "phenotypes": null, "pub_med_references": [ 19603024 ], "rating": "3", "representative_transcript": null, "transcripts": null, "variant": "Mutation", "variant_civic_url": null, "variant_origin": "Somatic", "variant_summary": null, "gene_description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer. Oncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors. Class 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors. Class 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors. Class 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase." }, { "asco_entry": null, "clinical_significance": "Resistance", "disease": "Colorectal Cancer", "doid": "9256", "drug_interaction_type": null, "drugs": [ "Cetuximab" ], "entrez_id": null, "evidence_civic_url": "https://civicdb.org/links/evidence_items/6306", "evidence_direction": "Supports", "evidence_level": "B", "evidence_statement": "This was a retrospective clinical study of 92 metastatic colorectal cancer patients who received cetuximab in conjunction with salvage chemotherapy (refractory to at least one line of treatment). Salvage chemotherapy was composed of 5-fluorouracil (5-FU) only, 5-FU + oxaliplatin, 5-FU + irinotecan, or 5-FU + oxaliplatin + irinotecan. The study assessed the relationship between BRAF mutation status in primary tumors and response to cetuximab-containing salvage chemotherapy, as measured by PFS. Of the 92 patients, 83 had wildtype BRAF and 9 had mutations in BRAF—including V600E and D594K. The study found that patients harboring a BRAF mutation were significantly more resistant to cetuximab-containing salvage chemotherapy than patients with wildtype BRAF (Median PFS: 2.0 and 3.9, respectively; p = .0005).", "evidence_status": "accepted", "evidence_type": "Predictive", "gene": "BRAF", "gene_civic_url": null, "last_review_date": "2023-01-09 21:46:33 UTC", "nct_ids": null, "normalized_drug": [ "Cetuximab" ], "phenotypes": null, "pub_med_references": [ 19603024 ], "rating": "3", "representative_transcript": null, "transcripts": null, "variant": "Mutation", "variant_civic_url": null, "variant_origin": "Somatic", "variant_summary": null, "gene_description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer. Oncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors. Class 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors. Class 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors. Class 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase." }, { "asco_entry": null, "clinical_significance": "Poor Outcome", "disease": "Colorectal Cancer", "doid": "9256", "drug_interaction_type": null, "drugs": null, "entrez_id": null, "evidence_civic_url": "https://civicdb.org/links/evidence_items/6307", "evidence_direction": "Supports", "evidence_level": "B", "evidence_statement": "This was a retrospective clinical study of 168 metastatic colorectal cancer patients who received first line chemotherapy (made up of 5-fluorouracil (5-FU) only, 5-FU + oxaliplatin, 5-FU + irinotecan, or 5-FU + oxaliplatin + irinotecan) alone or with monoclonal antibodies (bevacizumab or cetuximab). It assessed the relationship between BRAF mutation status in primary tumors and post treatment OS. Of 168 patients, 155 had wildtype BRAF and 13 had mutations in BRAF—including V600E and D594K. The study found that patients harboring a BRAF mutation had a significantly worse outcome than patients expressing wildtype BRAF, regardless of first line chemotherapy regimen or use of monoclonal antibody treatment (Median OS: 10.9 and 40.5 months, respectively; p <.0001).", "evidence_status": "accepted", "evidence_type": "Prognostic", "gene": "BRAF", "gene_civic_url": null, "last_review_date": "2023-01-09 21:46:33 UTC", "nct_ids": null, "normalized_drug": null, "phenotypes": null, "pub_med_references": [ 19603024 ], "rating": "3", "representative_transcript": null, "transcripts": null, "variant": "Mutation", "variant_civic_url": null, "variant_origin": "Somatic", "variant_summary": null, "gene_description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer. Oncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors. Class 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors. Class 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors. Class 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase." }, { "asco_entry": null, "clinical_significance": "Resistance", "disease": "Melanoma", "doid": "1909", "drug_interaction_type": null, "drugs": [ "Vemurafenib", "Dabrafenib" ], "entrez_id": null, "evidence_civic_url": "https://civicdb.org/links/evidence_items/6400", "evidence_direction": "Supports", "evidence_level": "B", "evidence_statement": "In a retrospective study of 44 relapsed melanoma patients harboring BRAF V600E or V600K (known BRAF inhibitor sensitizing mutations), MAPK pathway reactivation mechanisms were implicated in acquired resistance to BRAF inhibitor (vemurafenib or dabrafenib) monotherapy. The following MAPK pathway variants were found in progressive tumors with patient matched baseline tumors (some patients donated samples from multiple geographically/temporally distinct progressive tumors): NRAS mutations (G12D, G12R, G13R, Q61K, Q61R, Q61L) in 13/71 (18%) of progressive tumors, KRAS mutations (G12C, G12R, Q61H) in 5/71 (7%) of progressive tumors, mutant BRAF amplification (2-15 fold or 4-75 copies) in 11/57 (19%) of progressive tumors, mutant BRAF alternative splice variants (novel exon boundaries between 1/9, 1/11, 3/9) in 6/48 (13%) of progressive tumor RNA.", "evidence_status": "accepted", "evidence_type": "Predictive", "gene": "BRAF", "gene_civic_url": null, "last_review_date": "2023-01-09 21:46:57 UTC", "nct_ids": null, "normalized_drug": [ "Dabrafenib", "Vemurafenib" ], "phenotypes": null, "pub_med_references": [ 24265155 ], "rating": "3", "representative_transcript": null, "transcripts": null, "variant": "intron 10 rearrangement", "variant_civic_url": null, "variant_origin": "Somatic", "variant_summary": null, "gene_description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer. Oncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors. Class 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors. Class 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors. Class 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase." }, { "asco_entry": null, "clinical_significance": "Resistance", "disease": "Melanoma", "doid": "1909", "drug_interaction_type": null, "drugs": [ "Dabrafenib", "Vemurafenib" ], "entrez_id": null, "evidence_civic_url": "https://civicdb.org/links/evidence_items/6401", "evidence_direction": "Supports", "evidence_level": "B", "evidence_statement": "In a retrospective study of 44 relapsed melanoma patients harboring BRAF V600E or V600K (known BRAF inhibitor sensitizing mutations), MAPK pathway reactivation mechanisms were implicated in acquired resistance to BRAF inhibitor (vemurafenib or dabrafenib) monotherapy. The following MAPK pathway variants were found in progressive tumors with patient matched baseline tumors (some patients donated samples from multiple geographically/temporally distinct progressive tumors): NRAS mutations (G12D, G12R, G13R, Q61K, Q61R, Q61L) in 13/71 (18%) of progressive tumors, KRAS mutations (G12C, G12R, Q61H) in 5/71 (7%) of progressive tumors, mutant BRAF amplification (2-15 fold or 4-75 copies) in 11/57 (19%) of progressive tumors, mutant BRAF alternative splice variants (novel exon boundaries between 1/9, 1/11, 3/9) in 6/48 (13%) of progressive tumor RNA.", "evidence_status": "accepted", "evidence_type": "Predictive", "gene": "BRAF", "gene_civic_url": null, "last_review_date": "2023-01-09 21:46:57 UTC", "nct_ids": null, "normalized_drug": [ "Dabrafenib", "Vemurafenib" ], "phenotypes": null, "pub_med_references": [ 24265155 ], "rating": "3", "representative_transcript": null, "transcripts": null, "variant": "intron 9 rearrangement", "variant_civic_url": null, "variant_origin": "Somatic", "variant_summary": null, "gene_description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer. Oncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors. Class 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors. Class 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors. Class 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase." }, { "asco_entry": null, "clinical_significance": "Sensitivity/Response", "disease": "Melanoma", "doid": "1909", "drug_interaction_type": null, "drugs": [ "Trametinib", "Dabrafenib" ], "entrez_id": null, "evidence_civic_url": "https://civicdb.org/links/evidence_items/6937", "evidence_direction": "Supports", "evidence_level": "B", "evidence_statement": "In this Phase III trial (NCT01584648 COMBI-d), 423 previously untreated patients with unresectable stage IIIC or IV BRAF V600E or V600K mutant melanoma received dabrafenib and trametinib or dabrafenib alone with primary endpoint of progression free survival with secondary endpoints including disease response. The hazard ratio for progression or death in the dabrafenib–trametinib group was 0.75 (95% confidence interval, 0.57 to 0.99; P=0.03). Of 210 patients in the dabrafenib + trametinib group, 67% of patients had a response, which was 16 percentage points higher than in the dabrafenib-alone group (95% CI, 6 to 25; P=0.002).", "evidence_status": "accepted", "evidence_type": "Predictive", "gene": "BRAF", "gene_civic_url": null, "last_review_date": "2023-01-09 21:46:25 UTC", "nct_ids": [ "NCT01584648" ], "normalized_drug": [ "Dabrafenib, Trametinib" ], "phenotypes": null, "pub_med_references": [ 25265492 ], "rating": "5", "representative_transcript": null, "transcripts": null, "variant": "V600", "variant_civic_url": null, "variant_origin": "Somatic", "variant_summary": null, "gene_description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer. Oncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors. Class 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors. Class 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors. Class 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase." }, { "asco_entry": null, "clinical_significance": "Sensitivity/Response", "disease": "Melanoma", "doid": "1909", "drug_interaction_type": null, "drugs": [ "Vemurafenib", "Cobimetinib" ], "entrez_id": null, "evidence_civic_url": "https://civicdb.org/links/evidence_items/6966", "evidence_direction": "Supports", "evidence_level": "B", "evidence_statement": "In this Phase 1b study, 129 patients with unresectable or metastatic melanoma were verified for BRAF V600 mutation using the cobas 4800 mutation test were selected who had progressed on vemurafenib (66 patients) or never received BRAF inhibitor (63 patients). The combination of vemurafenib and cobimetinib was deemed safe and tolerable. Confirmed objective responses were seen in 15% of vemurafenib progressed patients and median progression-free survival was 2.8 months (95% CI 2·6–3·4). Confirmed objective responses were seen in 87% of patients who had never received BRAF inhibitor, including 10% with complete response. Median progression-free survival was 13.7 months (95% CI 10·1–17·5). The majority of patients had BRAF V600E mutation. Post-hoc sequencing of 94 tumor samples indicated seven tumors with a mutation other than BRAF V600E.", "evidence_status": "accepted", "evidence_type": "Predictive", "gene": "BRAF", "gene_civic_url": null, "last_review_date": "2023-01-09 21:46:25 UTC", "nct_ids": [ "NCT01271803" ], "normalized_drug": [ "Cobimetinib, Vemurafenib" ], "phenotypes": null, "pub_med_references": [ 25037139 ], "rating": "3", "representative_transcript": null, "transcripts": null, "variant": "V600", "variant_civic_url": null, "variant_origin": "Somatic", "variant_summary": null, "gene_description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer. Oncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors. Class 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors. Class 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors. Class 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase." }, { "asco_entry": null, "clinical_significance": "Positive", "disease": "Pilocytic Astrocytoma", "doid": "4851", "drug_interaction_type": null, "drugs": null, "entrez_id": null, "evidence_civic_url": "https://civicdb.org/links/evidence_items/7148", "evidence_direction": "Supports", "evidence_level": "B", "evidence_statement": "Genetic alterations in pilocytic astrocytoma (PA) were evaluated. Whole-genome sequencing of normal (blood) and tumor samples (n=96) was performed along with corresponding RNA-Seq (n=73) and mate-pair (MP) sequencing (n=68). Several known events activating the MAPK pathway were identified with KIAA1549-BRAF fusion being the most frequent variants (70 of 96 cases, 73%). Importantly, all but one of the cerebellar PA harbored a BRAF fusion (47 of 48 samples, 98%) with this one exception having a KRAS alteration.", "evidence_status": "accepted", "evidence_type": "Diagnostic", "gene": "BRAF", "gene_civic_url": null, "last_review_date": "2023-01-09 21:46:36 UTC", "nct_ids": null, "normalized_drug": null, "phenotypes": null, "pub_med_references": [ 23817572 ], "rating": "5", "representative_transcript": null, "transcripts": null, "variant": "KIAA1549::BRAF", "variant_civic_url": null, "variant_origin": "Somatic", "variant_summary": null, "gene_description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer. Oncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors. Class 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors. Class 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors. Class 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase." }, { "asco_entry": null, "clinical_significance": "Poor Outcome", "disease": "Colorectal Cancer", "doid": "9256", "drug_interaction_type": null, "drugs": null, "entrez_id": null, "evidence_civic_url": "https://civicdb.org/links/evidence_items/7158", "evidence_direction": "Supports", "evidence_level": "B", "evidence_statement": "In the Medical Research Council (MRC) COIN trial, ISRCTN27286448, patients who presented with advanced colorectal cancer were randomly assigned to chemotherapy (oxaliplatin and fluoropyrimidine; arm A), or chemotherapy plus cetuximab (arm B). Median overall survival was found to differ by mutation, regardless of treatment. Median overall survival was 8.8 months (IQR 4.5-27) for patients with BRAF variants, 14.4 months (IQR 8.5-24.0) for patients with KRAS variants, and 20.1 months (IQR 11.5-31.7) for wildtype patients. BRAF mutations were found in 102/1291 samples (7.90%), and of these, 12 were D594G and 90 V600E.", "evidence_status": "accepted", "evidence_type": "Prognostic", "gene": "BRAF", "gene_civic_url": null, "last_review_date": "2023-01-09 21:46:33 UTC", "nct_ids": null, "normalized_drug": null, "phenotypes": null, "pub_med_references": [ 21641636 ], "rating": "4", "representative_transcript": null, "transcripts": null, "variant": "Mutation", "variant_civic_url": null, "variant_origin": "Somatic", "variant_summary": null, "gene_description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer. Oncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors. Class 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors. Class 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors. Class 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase." }, { "asco_entry": null, "clinical_significance": "Poor Outcome", "disease": "Colorectal Cancer", "doid": "9256", "drug_interaction_type": null, "drugs": null, "entrez_id": null, "evidence_civic_url": "https://civicdb.org/links/evidence_items/7159", "evidence_direction": "Supports", "evidence_level": "B", "evidence_statement": "A meta analysis was performed using data from 21 published studies (n = 9885 patients) to assess prognostic value of BRAF mutations in colorectal cancer. When evaluating 14 studies (n = 7778 patients), the odds ratio (OR) of a proximal lesion, which is associated with greater mortality in colon cancer, was increased for patients with BRAF mutations (OR 5.222, 95% CI 3.801–7.174, P < 0.001). When evaluating 4 studies (n = 1526 patients), the odds ratio of T4 tumors, which indicates tumor growth past bowel lining, was increased for patients with BRAF mutations (OR 1.761, 95% CI 1.164–2.663, P = 0.007). When evaluating 8 studies (n = 2786 patients), the odds ratio of poor tumor differentiation was increased in patients with BRAF mutations (OR 3.816, 95% CI 2.714–5.365, P < 0.001). These results support that BRAF mutations indicate poor prognosis for patients with colorectal cancer.", "evidence_status": "accepted", "evidence_type": "Prognostic", "gene": "BRAF", "gene_civic_url": null, "last_review_date": "2023-01-09 21:46:33 UTC", "nct_ids": null, "normalized_drug": null, "phenotypes": null, "pub_med_references": [ 24112392 ], "rating": "4", "representative_transcript": null, "transcripts": null, "variant": "Mutation", "variant_civic_url": null, "variant_origin": "Somatic", "variant_summary": null, "gene_description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer. Oncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors. Class 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors. Class 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors. Class 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase." }, { "asco_entry": null, "clinical_significance": "Better Outcome", "disease": "Childhood Low-grade Glioma", "doid": "0080830", "drug_interaction_type": null, "drugs": null, "entrez_id": null, "evidence_civic_url": "https://civicdb.org/links/evidence_items/7193", "evidence_direction": "Supports", "evidence_level": "B", "evidence_statement": "KIAA1549-BRAF fusion was identified in 87 of 272 patients with PLGGs using Fluorescence In situ hybridization (FISH) analysis. This mutation was strongly associated with a greater progression-free survival (p=0.0017) and overall survival (p=0.0029) [fusion-positive (n=64) vs fusion-negative (n=141)].", "evidence_status": "accepted", "evidence_type": "Prognostic", "gene": "BRAF", "gene_civic_url": null, "last_review_date": "2023-01-09 21:46:36 UTC", "nct_ids": null, "normalized_drug": null, "phenotypes": [ "Early young adult onset", "Pediatric onset" ], "pub_med_references": [ 29948154 ], "rating": "4", "representative_transcript": null, "transcripts": null, "variant": "KIAA1549::BRAF", "variant_civic_url": null, "variant_origin": "Somatic", "variant_summary": null, "gene_description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer. Oncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors. Class 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors. Class 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors. Class 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase." }, { "asco_entry": null, "clinical_significance": "Sensitivity/Response", "disease": "Childhood Low-grade Glioma", "doid": "0080830", "drug_interaction_type": null, "drugs": [ "Trametinib", "Everolimus" ], "entrez_id": null, "evidence_civic_url": "https://civicdb.org/links/evidence_items/7199", "evidence_direction": "Supports", "evidence_level": "D", "evidence_statement": "This preclinical study proposed to use a combination therapy of an MEK inhibitor (e.g. trametinib) and an mTOR inhibitor (e.g. everolimus) for the treatment of pediatric low-grade gliomas (PLGGs) with BRAF fusions to evade acquired resistance to MEK targeted therapy. The PI3K/Akt/mTOR pathway was identified as a resistance mechanism to MEKi treatment based on RNASeq and GSEA analysis. Using flank xenograft model, mice were injected with NIH3T3 cells expressing KIAA1549-BRAF fusions and treated daily with trametinib, everolimus either alone or combined with each other (n=~10 for each treatment arm). Combination therapy (Trametinib 1mg/kg+ Everolimus 10mg/kg) resulted in better suppression in tumor growth than single-agent treatment. Similarly, combination treatment strongly reduced colony formation as well as pERK and pS6 levels, showing on target effects.", "evidence_status": "accepted", "evidence_type": "Predictive", "gene": "BRAF", "gene_civic_url": null, "last_review_date": "2023-01-09 21:46:36 UTC", "nct_ids": null, "normalized_drug": [ "Everolimus", "Trametinib" ], "phenotypes": null, "pub_med_references": [ 29156677 ], "rating": "2", "representative_transcript": null, "transcripts": null, "variant": "KIAA1549::BRAF", "variant_civic_url": null, "variant_origin": "Somatic", "variant_summary": null, "gene_description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer. Oncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors. Class 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors. Class 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors. Class 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase." }, { "asco_entry": null, "clinical_significance": "Better Outcome", "disease": "Childhood Low-grade Glioma", "doid": "0080830", "drug_interaction_type": null, "drugs": null, "entrez_id": null, "evidence_civic_url": "https://civicdb.org/links/evidence_items/7200", "evidence_direction": "Supports", "evidence_level": "B", "evidence_statement": "Hawkins et al. (2011) retrospectively studied 70 consecutive patient with incompletely resected pediatric low-grade astrocytomas (PLGA). KIAA1549-BRAF fusion was identified in 60% of cases in this cohort. Multi-variant analysis suggested that KIAA1549-BRAF fusion was the most significant favorable prognosis factor in incompletely resected PLGA and was independent of location, pathology, and age. Five-year PFS of fusion positive and fusion negative patients were 61% +/- 8% and 18% +/- 8% (P=0.0004), respectively. These results suggested that KIAA1549-BRAF fusion confers a less aggressive clinical phenotype on PLGA and may explain their tendency to growth arrest.", "evidence_status": "accepted", "evidence_type": "Prognostic", "gene": "BRAF", "gene_civic_url": null, "last_review_date": "2023-01-09 21:46:36 UTC", "nct_ids": null, "normalized_drug": null, "phenotypes": null, "pub_med_references": [ 21610142 ], "rating": "4", "representative_transcript": null, "transcripts": null, "variant": "KIAA1549::BRAF", "variant_civic_url": null, "variant_origin": "Somatic", "variant_summary": null, "gene_description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer. Oncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors. Class 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors. Class 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors. Class 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase." }, { "asco_entry": null, "clinical_significance": "Sensitivity/Response", "disease": "Melanoma", "doid": "1909", "drug_interaction_type": null, "drugs": [ "Binimetinib", "Encorafenib" ], "entrez_id": null, "evidence_civic_url": "https://civicdb.org/links/evidence_items/7287", "evidence_direction": "Supports", "evidence_level": "A", "evidence_statement": "In a phase 3 trial, patients with melanoma with BRAF V600E or V600K mutation were randomly assigned to encorafenib plus binimetinib or vemurafenib or encorafenib. mPFS was 14·9 months (95% CI 11·0-18·5) in the encorafenib plus binimetinib group and 7·3 months (5·6-8·2) in the vemurafenib group (hazard ratio [HR] 0·54, 95% CI 0·41-0·71; two-sided p<0·0001)", "evidence_status": "accepted", "evidence_type": "Predictive", "gene": "BRAF", "gene_civic_url": null, "last_review_date": "2023-01-09 21:46:25 UTC", "nct_ids": [ "NCT01909453" ], "normalized_drug": [ "Binimetinib, Encorafenib" ], "phenotypes": null, "pub_med_references": [ 29573941 ], "rating": "5", "representative_transcript": null, "transcripts": null, "variant": "V600", "variant_civic_url": null, "variant_origin": "Somatic", "variant_summary": null, "gene_description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer. Oncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors. Class 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors. Class 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors. Class 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase." }, { "asco_entry": null, "clinical_significance": "Sensitivity/Response", "disease": "Spindle Cell Sarcoma", "doid": "4235", "drug_interaction_type": null, "drugs": [ "Bevacizumab", "Temsirolimus", "Sorafenib" ], "entrez_id": null, "evidence_civic_url": "https://civicdb.org/links/evidence_items/7312", "evidence_direction": "Supports", "evidence_level": "C", "evidence_statement": "A patients with malignant spindle cell tumor treated as as soft tissue sarcoma harboring KIAA1549-BRAF fusion were treated with sorafenib in combination with bevacizumab and temsirolimus. Tumor of the chest wall showed good response.", "evidence_status": "accepted", "evidence_type": "Predictive", "gene": "BRAF", "gene_civic_url": null, "last_review_date": "2023-01-09 21:46:36 UTC", "nct_ids": null, "normalized_drug": [ "Bevacizumab", "Sorafenib", "Temsirolimus" ], "phenotypes": null, "pub_med_references": [ 26314551 ], "rating": "2", "representative_transcript": null, "transcripts": null, "variant": "KIAA1549::BRAF", "variant_civic_url": null, "variant_origin": "Somatic", "variant_summary": null, "gene_description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer. Oncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors. Class 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors. Class 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors. Class 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase." }, { "asco_entry": null, "clinical_significance": "Positive", "disease": "Pilocytic Astrocytoma", "doid": "4851", "drug_interaction_type": null, "drugs": null, "entrez_id": null, "evidence_civic_url": "https://civicdb.org/links/evidence_items/7319", "evidence_direction": "Supports", "evidence_level": "B", "evidence_statement": "This study identified a novel rearrangement event between the uncharacterized gene KIAA-1549 and BRAF in 66% (29 of 44) of pilocytic astrocytoma but not in 244 higher-grade astrocytomas that were evaluated. An in vitro study further showed that this fusion gene lacks the N-terminal BRAF auto-regulatory domain, leading to constitutive activation of BRAF.", "evidence_status": "accepted", "evidence_type": "Diagnostic", "gene": "BRAF", "gene_civic_url": null, "last_review_date": "2023-01-09 21:46:36 UTC", "nct_ids": null, "normalized_drug": null, "phenotypes": null, "pub_med_references": [ 18974108 ], "rating": "4", "representative_transcript": null, "transcripts": null, "variant": "KIAA1549::BRAF", "variant_civic_url": null, "variant_origin": "Somatic", "variant_summary": null, "gene_description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer. Oncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors. Class 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors. Class 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors. Class 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase." }, { "asco_entry": null, "clinical_significance": "Oncogenicity", "disease": "Pilocytic Astrocytoma", "doid": "4851", "drug_interaction_type": null, "drugs": null, "entrez_id": null, "evidence_civic_url": "https://civicdb.org/links/evidence_items/7337", "evidence_direction": "Supports", "evidence_level": "D", "evidence_statement": "This study identified a novel rearrangement event between the uncharacterized gene KIAA-1549 and BRAF in 66% (29 of 44) of pilocytic astrocytomas. The fusion gene was shown to delete the N-terminal BRAF auto-regulatory domain which in vitro assays indicated leads to constitutive activation of BRAF. Cos7 cells were transfected with two isoforms of KIAA1549-BRAF (both exon 16:exon 9), BRAF V600E, or wildtype BRAF and evaluated activity via BRAF kinase assay. Both fusion isoforms showed similar or higher kinase activity than V600E transfected cells. NIH3T3 cells transfected with V600E or the short fusion isoform also demonstrated anchorage-independent growth in soft agarose.", "evidence_status": "accepted", "evidence_type": "Oncogenic", "gene": "BRAF", "gene_civic_url": null, "last_review_date": "2023-02-03 19:36:14 UTC", "nct_ids": null, "normalized_drug": null, "phenotypes": null, "pub_med_references": [ 18974108 ], "rating": "3", "representative_transcript": null, "transcripts": null, "variant": "KIAA1549::BRAF", "variant_civic_url": null, "variant_origin": "Somatic", "variant_summary": null, "gene_description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer. Oncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors. Class 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors. Class 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors. Class 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase." }, { "asco_entry": { "asco_citation_id": "147167", "asco_abstract_id": "3505" }, "clinical_significance": "Sensitivity/Response", "disease": "Colorectal Cancer", "doid": "9256", "drug_interaction_type": null, "drugs": [ "Vemurafenib", "Irinotecan", "Cetuximab" ], "entrez_id": null, "evidence_civic_url": "https://civicdb.org/links/evidence_items/7355", "evidence_direction": "Supports", "evidence_level": "B", "evidence_statement": "A randomized clinical trial was done with metastatic colorectal cancer (mCRC) patients (50 in the control group, 49 in the experimental group) with BRAF V600 mutations and RAS wild type that were enrolled from December 2014 to April 2016. The patients were randomized into groups with irinotecan and cetuximab with vemurafenib (VIC group) or without (IC group). The VIC group showed an improvement of progression of free survival (HR 0.42, 95% CI: 0.26 to 0.66, p < 0.001) with a median value of 4.4 months compared to 2.0 months for the IC group. In addition, for the VIC group, there was a 16% drug response rate while the IC group had a 4% drug response rate (p-value = 0.08). Some grade 3/4 adverse events were higher in the experimental arm, and skin toxicity and fatigue showed no increase.", "evidence_status": "accepted", "evidence_type": "Predictive", "gene": "BRAF", "gene_civic_url": null, "last_review_date": "2023-01-09 21:46:25 UTC", "nct_ids": [ "NCT02164916" ], "normalized_drug": [ "Cetuximab", "Irinotecan", "Vemurafenib" ], "phenotypes": null, "pub_med_references": null, "rating": "3", "representative_transcript": null, "transcripts": null, "variant": "V600", "variant_civic_url": null, "variant_origin": "Somatic", "variant_summary": null, "gene_description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer. Oncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors. Class 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors. Class 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors. Class 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase." }, { "asco_entry": null, "clinical_significance": "Resistance", "disease": "Childhood Pilocytic Astrocytoma", "doid": "6812", "drug_interaction_type": null, "drugs": [ "Vemurafenib", "Sorafenib" ], "entrez_id": null, "evidence_civic_url": "https://civicdb.org/links/evidence_items/7402", "evidence_direction": "Supports", "evidence_level": "D", "evidence_statement": "A pilocytic astrocytoma (PA) cell line named DKFZ-BT66 was generated from a 2-year old patient with the disease. Expression of KIAA1549-BRAF fusion in this cell line was identified. Treatment with sorafenib or vemurafenib resulted in paradoxical activation of MAPK/ERK as seen by increased pERK in western blots. Authors note that their observation aligns with results from a phase II clinical trial wherein PA patients experienced tumor growth under sorafenib treatment induced by paradoxical MAPK activation.", "evidence_status": "accepted", "evidence_type": "Predictive", "gene": "BRAF", "gene_civic_url": null, "last_review_date": "2023-01-09 21:46:36 UTC", "nct_ids": null, "normalized_drug": [ "Sorafenib", "Vemurafenib" ], "phenotypes": [ "Infantile onset" ], "pub_med_references": [ 28002790 ], "rating": "2", "representative_transcript": null, "transcripts": null, "variant": "KIAA1549::BRAF", "variant_civic_url": null, "variant_origin": "Somatic", "variant_summary": null, "gene_description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer. Oncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors. Class 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors. Class 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors. Class 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase." }, { "asco_entry": null, "clinical_significance": "Sensitivity/Response", "disease": "Melanoma", "doid": "1909", "drug_interaction_type": null, "drugs": [ "BRAF Inhibitor", "Mitogen-Activated Protein Kinase Kinase Inhibitor" ], "entrez_id": null, "evidence_civic_url": "https://civicdb.org/links/evidence_items/7630", "evidence_direction": "Supports", "evidence_level": "C", "evidence_statement": "In a retrospective study from 20 institutes in 4 countries, the efficacy of BRAF inhibitor and/or MEK inhibitor in patients with melanoma harboring BRAF nonV600E/K mutations were evaluated. Treated with BRAF inhibitor monotherapy, response rate were 27%(4/15) for V600R, 100%(2/2) for V600D, 0% (0/2) for V600_K601>E, 0% (0/1) for V600G, 0% (0/1) for V600L, 0% (0/1) for V600_S602>DT, 0% (0/5) for L597, 0% (0/6) for K601E, 0% (0/2) for G469, 0% (0/1) for G593D,and 0% (0/1) for T599_V600insT Treated with MEK inhibitor monotherapy, response rate were 100% (1/1) for L597, and 0% (0/1) for K601E. Treated with BRAF inhibitor and MEK inhibitor combination thearpy, response rate were 55% (16/29) for V600R, 67% (2/3) for V600D, 50% (1/2) for V600_K601>E, 50% (1/2) for V600M, 22% (2/9) for L597,25% (1/4) for K601E, 67% (2/3) for G469, and 0% (0/1) for A598V.", "evidence_status": "accepted", "evidence_type": "Predictive", "gene": "BRAF", "gene_civic_url": null, "last_review_date": "2023-01-09 21:47:02 UTC", "nct_ids": null, "normalized_drug": [ "Braf Inhibitor" ], "phenotypes": null, "pub_med_references": [ 31580757 ], "rating": "3", "representative_transcript": null, "transcripts": null, "variant": "V600_K601>E", "variant_civic_url": null, "variant_origin": "Somatic", "variant_summary": null, "gene_description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer. Oncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors. Class 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors. Class 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors. Class 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase." }, { "asco_entry": null, "clinical_significance": "Sensitivity/Response", "disease": "Melanoma", "doid": "1909", "drug_interaction_type": null, "drugs": [ "BRAF Inhibitor", "Mitogen-Activated Protein Kinase Kinase Inhibitor" ], "entrez_id": null, "evidence_civic_url": "https://civicdb.org/links/evidence_items/7634", "evidence_direction": "Supports", "evidence_level": "B", "evidence_statement": "In a retrospective study from 20 institutes in 4 countries, the efficacy of BRAF inhibitor and/or MEK inhibitor in patients with melanoma harboring BRAF nonV600E/K mutations were evaluated. Treated with BRAF inhibitor monotherapy, response rate were 27%(4/15) for V600R, 100%(2/2) for V600D, 0% (0/2) for V600_K601>E, 0% (0/1) for V600G, 0% (0/1) for V600L, 0% (0/1) for V600_S602>DT, 0% (0/5) for L597, 0% (0/6) for K601E, 0% (0/2) for G469, 0% (0/1) for G593D,and 0% (0/1) for T599_V600insT Treated with MEK inhibitor monotherapy, response rate were 100% (1/1) for L597, and 0% (0/1) for K601E. Treated with BRAF inhibitor and MEK inhibitor combination thearpy, response rate were 55% (16/29) for V600R, 67% (2/3) for V600D, 50% (1/2) for V600_K601>E, 50% (1/2) for V600M, 22% (2/9) for L597,25% (1/4) for K601E, 67% (2/3) for G469, and 0% (0/1) for A598V.", "evidence_status": "accepted", "evidence_type": "Predictive", "gene": "BRAF", "gene_civic_url": null, "last_review_date": "2023-01-09 21:47:02 UTC", "nct_ids": null, "normalized_drug": [ "Braf Inhibitor" ], "phenotypes": null, "pub_med_references": [ 31580757 ], "rating": "3", "representative_transcript": null, "transcripts": null, "variant": "G469", "variant_civic_url": null, "variant_origin": "Somatic", "variant_summary": null, "gene_description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer. Oncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors. Class 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors. Class 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors. Class 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase." }, { "asco_entry": null, "clinical_significance": "Resistance", "disease": "Melanoma", "doid": "1909", "drug_interaction_type": null, "drugs": [ "Trametinib", "Dabrafenib" ], "entrez_id": null, "evidence_civic_url": "https://civicdb.org/links/evidence_items/7677", "evidence_direction": "Supports", "evidence_level": "C", "evidence_statement": "In a retrospective study, authors analyzed BRAF V600 mutated melanoma metastases derived from 10 patients treated with the combination of dabrafenib and trametinib for resistance mechanisms and genetic correlates of response. An acquired resistance mechanism activating the MAPK pathway was identified in 9 tumors; BRAF amplification (n=4), MEK1/2 mutation (n=3), NRAS mutations (n=3). Among them, mutual exclusive alterations were BRAF amplification (n=4), MEK2 C125S (n=1), and NRAS Q61K (n=2).", "evidence_status": "accepted", "evidence_type": "Predictive", "gene": "BRAF", "gene_civic_url": null, "last_review_date": "2023-01-09 21:46:44 UTC", "nct_ids": null, "normalized_drug": [ "Dabrafenib, Trametinib" ], "phenotypes": null, "pub_med_references": [ 25452114 ], "rating": "4", "representative_transcript": null, "transcripts": null, "variant": "Amplification", "variant_civic_url": null, "variant_origin": "Somatic", "variant_summary": null, "gene_description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer. Oncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors. Class 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors. Class 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors. Class 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase." }, { "asco_entry": null, "clinical_significance": "Sensitivity/Response", "disease": "Pancreatic Cancer", "doid": "1793", "drug_interaction_type": null, "drugs": [ "Trametinib" ], "entrez_id": null, "evidence_civic_url": "https://civicdb.org/links/evidence_items/7730", "evidence_direction": "Supports", "evidence_level": "C", "evidence_statement": "In a case report, a patient with pancreatic cancer harboring BRAF N486-P490del was treated with trametinib. Within 4 weeks of initiating therapy, her serum CA19-9 had fallen from 36,000 to 8,100 U/mL, and the radiographic partial response was revealed by CT at 8 weeks after initiation of trametinib. cfDNA measurements for BRAF and TP53 alleles revealed a dramatic decline in response to trametinib. After 6 months of therapy, radiographic progression was identified.", "evidence_status": "accepted", "evidence_type": "Predictive", "gene": "BRAF", "gene_civic_url": null, "last_review_date": "2023-01-09 21:47:02 UTC", "nct_ids": null, "normalized_drug": [ "Trametinib" ], "phenotypes": null, "pub_med_references": [ 29903880 ], "rating": "3", "representative_transcript": null, "transcripts": null, "variant": "N486_P490del", "variant_civic_url": null, "variant_origin": "Somatic", "variant_summary": null, "gene_description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer. Oncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors. Class 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors. Class 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors. Class 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase." }, { "asco_entry": null, "clinical_significance": "Sensitivity/Response", "disease": "Transitional Cell Carcinoma", "doid": "2671", "drug_interaction_type": null, "drugs": [ "Trametinib" ], "entrez_id": null, "evidence_civic_url": "https://civicdb.org/links/evidence_items/7763", "evidence_direction": "Supports", "evidence_level": "C", "evidence_statement": "In a case report, a patient with metastatic urothelial carcinoma harboring an NRF1-BRAF fusion was treated with trametinib. After two and a half months of treatment, MRI revealed 48.4% decrease in size of liver metastasis.", "evidence_status": "accepted", "evidence_type": "Predictive", "gene": "BRAF", "gene_civic_url": null, "last_review_date": "2023-01-09 21:47:03 UTC", "nct_ids": null, "normalized_drug": [ "Trametinib" ], "phenotypes": null, "pub_med_references": [ 31010895 ], "rating": "3", "representative_transcript": null, "transcripts": null, "variant": "NRF1::BRAF", "variant_civic_url": null, "variant_origin": "Somatic", "variant_summary": null, "gene_description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer. Oncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors. Class 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors. Class 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors. Class 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase." }, { "asco_entry": null, "clinical_significance": "Sensitivity/Response", "disease": "Solid Tumor", "doid": null, "drug_interaction_type": null, "drugs": [ "Trametinib" ], "entrez_id": null, "evidence_civic_url": "https://civicdb.org/links/evidence_items/7855", "evidence_direction": "Does Not Support", "evidence_level": "B", "evidence_statement": "In a phase II basket trial (NCI-MATCH), patients with solid tumors or hematologic malignancies harboring BRAF non-V600 mutations were treated with trametinib. Among 50 patients assigned, 32 were eligible and received therapy with trametinib. Most common tumor histopathologic subtypes were GI cancers (n=8, of which 7 were colorectal adenocarcinoma), lung adenocarcinoma (n=9), prostate adenocarcinoma (n=4), gynecologic cancer (n=4), BRAF alterations included BRAF fusion (n=1), G464 (n=2), G466 (n=4), G469 (n=7), N581 (n=3), D594 (n=11), L597 (n=2) and K601 (n=1). Of the 32 patients evaluable for efficacy endpoints, the response rate was 3% (3/32). The patient with a partial response had invasive breast cancer with a BRAF G469E mutation. The median PFS was 1.8 months and the median OS was 5.7 months.", "evidence_status": "accepted", "evidence_type": "Predictive", "gene": "BRAF", "gene_civic_url": null, "last_review_date": "2023-01-09 21:46:58 UTC", "nct_ids": null, "normalized_drug": [ "Trametinib" ], "phenotypes": null, "pub_med_references": [ 31924734 ], "rating": "4", "representative_transcript": null, "transcripts": null, "variant": "Non-V600", "variant_civic_url": null, "variant_origin": "Somatic", "variant_summary": null, "gene_description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer. Oncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors. Class 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors. Class 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors. Class 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase." }, { "asco_entry": null, "clinical_significance": "Sensitivity/Response", "disease": "Childhood Pilocytic Astrocytoma", "doid": "6812", "drug_interaction_type": null, "drugs": [ "Selumetinib" ], "entrez_id": null, "evidence_civic_url": "https://civicdb.org/links/evidence_items/8943", "evidence_direction": "Supports", "evidence_level": "D", "evidence_statement": "In this preclinical experiment, a pediatric pilocytic astrocytoma cell line (DKFZ-BT66) harboring KIAA1549:BRAF fusion was generated from a two year old patient. Treatment with selumetinib resulted in a significant decrease in viable cell count at concentrations of 10µM. Treatment with selumetinib fully abrogated ERK activation at concentrations of 0.1μM for as long as 120 hours. Authors note that inhibitory effects were more pronounced in cells treated with trametinib than cells treated with selumetinib.", "evidence_status": "accepted", "evidence_type": "Predictive", "gene": "BRAF", "gene_civic_url": null, "last_review_date": "2023-01-09 21:46:36 UTC", "nct_ids": null, "normalized_drug": [ "Selumetinib" ], "phenotypes": [ "Childhood onset" ], "pub_med_references": [ 28002790 ], "rating": "2", "representative_transcript": null, "transcripts": null, "variant": "KIAA1549::BRAF", "variant_civic_url": null, "variant_origin": "Somatic", "variant_summary": null, "gene_description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer. Oncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors. Class 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors. Class 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors. Class 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase." }, { "asco_entry": null, "clinical_significance": "Sensitivity/Response", "disease": "Childhood Pilocytic Astrocytoma", "doid": "6812", "drug_interaction_type": null, "drugs": [ "Trametinib" ], "entrez_id": null, "evidence_civic_url": "https://civicdb.org/links/evidence_items/8944", "evidence_direction": "Supports", "evidence_level": "D", "evidence_statement": "In this preclinical experiment, a pediatric pilocytic astrocytoma cell line (DKFZ-BT66) harboring KIAA1549:BRAF fusion was generated from a two year old patient. Treatment with trametinib resulted in a significant decrease in viable cell count at concentrations of 100nM and above. Trametinib also fully abrogated ERK activation at concentrations of 0.1μM for as long as 120 hours. Authors note that inhibitory effects were more pronounced in cells treated with trametinib than cells treated with selumetinib.", "evidence_status": "accepted", "evidence_type": "Predictive", "gene": "BRAF", "gene_civic_url": null, "last_review_date": "2023-01-09 21:46:36 UTC", "nct_ids": null, "normalized_drug": [ "Trametinib" ], "phenotypes": [ "Infantile onset" ], "pub_med_references": [ 28002790 ], "rating": "3", "representative_transcript": null, "transcripts": null, "variant": "KIAA1549::BRAF", "variant_civic_url": null, "variant_origin": "Somatic", "variant_summary": null, "gene_description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer. Oncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors. Class 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors. Class 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors. Class 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase." }, { "asco_entry": null, "clinical_significance": "Oncogenicity", "disease": "Cancer", "doid": "162", "drug_interaction_type": null, "drugs": null, "entrez_id": null, "evidence_civic_url": "https://civicdb.org/links/evidence_items/9527", "evidence_direction": "Supports", "evidence_level": "D", "evidence_statement": "The BRAF mutation G463E resulted in elevated kinase activity relative to wild-type BRAF in vitro. B-RAF activity was determined using kinase dead MEK as a substrate. G463E activity was 28 times higher than basal WT BRAF. The authors classified G463E activity as intermediate since its kinase activity was between basal WT BRAF and G12V RAS-activated WT B-RAF cells. In comparison, some BRAF variants displayed high kinase activity above the G12V RAS-activated WT BRAF cells. NIH3T3 transformation assay yielded 24 +/- 14 foci/ng of transfected BRAF DNA, in comparison to WT, which yielded zero foci, indicating an oncogenic effect of BRAF G463E.", "evidence_status": "accepted", "evidence_type": "Oncogenic", "gene": "BRAF", "gene_civic_url": null, "last_review_date": "2023-02-21 18:37:31 UTC", "nct_ids": null, "normalized_drug": null, "phenotypes": null, "pub_med_references": [ 15035987 ], "rating": "3", "representative_transcript": null, "transcripts": null, "variant": "G463E", "variant_civic_url": null, "variant_origin": "Unknown", "variant_summary": null, "gene_description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer. Oncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors. Class 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors. Class 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors. Class 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase." } ] }, "dbnsfp_genes": { "version": "4.8", "items": [ { "kegg": { "id": [ "hsa04010", "hsa04012", "hsa04150", "hsa04510", "hsa04650", "hsa04720", "hsa04730", "hsa04810", "hsa04910", "hsa05210", "hsa05211", "hsa05212", "hsa05213", "hsa05214", "hsa05215", "hsa05216", "hsa05218", "hsa05219", "hsa05220", "hsa05221", "hsa05223" ], "full": [ "MAPK signaling pathway", "ErbB signaling pathway", "mTOR signaling pathway", "Focal adhesion", "Natural killer cell mediated cytotoxicity", "Long-term potentiation", "Long-term depression", "Regulation of actin cytoskeleton", "Insulin signaling pathway", "Colorectal cancer", "Renal cell carcinoma", "Pancreatic cancer", "Endometrial cancer", "Glioma", "Prostate cancer", "Thyroid cancer", "Melanoma", "Bladder cancer", "Chronic myeloid leukemia", "Acute myeloid leukemia", "Non-small cell lung cancer" ] }, "expressions_rpkm": null, "gene_symbol": "BRAF", "p_hi": 0.9540000000000001, "gdi": 63.21, "gdi_phred": 1.627, "loftool_score": 0.021200000000000004, "hipred": true, "hipred_score": 0.8434, "ghis": 0.5588000000000001, "p_rec": null, "rvis_evs": -0.6000000000000001, "rvis_evs_percentile": "17.75%", "essential_gene": "Essential", "essential_crispr": "Non essential", "essential_crispr2": "Context-specific essential", "essential_mutagenesis": "KBM7-specific essential", "known_recessive_info": null, "indispensability_score": 0.8531000000000001, "indispensability_pred": "Essential", "go": { "molecular_function": [ "protein kinase activity", "protein serine/threonine kinase activity", "MAP kinase kinase kinase activity", "calcium ion binding", "protein binding", "ATP binding", "small GTPase binding", "mitogen-activated protein kinase kinase binding", "identical protein binding", "protein heterodimerization activity" ], "cellular_component": [ "nucleus", "mitochondrion", "cytosol", "plasma membrane", "neuron projection", "intracellular membrane-bounded organelle", "cell body" ], "biological_process": [ "MAPK cascade", "activation of MAPKK activity", "myeloid progenitor cell differentiation", "protein phosphorylation", "visual learning", "animal organ morphogenesis", "positive regulation of gene expression", "negative regulation of fibroblast migration", "positive regulation of glucose transmembrane transport", "thyroid gland development", "positive regulation of peptidyl-serine phosphorylation", "somatic stem cell population maintenance", "cellular response to drug", "regulation of cell population proliferation", "negative regulation of apoptotic process", "CD4-positive, alpha-beta T cell differentiation", "CD4-positive or CD8-positive, alpha-beta T cell lineage commitment", "response to peptide hormone", "negative regulation of neuron apoptotic process", "regulation of T cell differentiation", "thymus development", "positive regulation of axon regeneration", "positive regulation of axonogenesis", "T cell receptor signaling pathway", "protein heterooligomerization", "positive regulation of stress fiber assembly", "response to cAMP", "long-term synaptic potentiation", "head morphogenesis", "face development", "positive regulation of ERK1 and ERK2 cascade", "trehalose metabolism in response to stress", "cellular response to calcium ion", "establishment of protein localization to membrane", "positive regulation of substrate adhesion-dependent cell spreading", "cellular response to nerve growth factor stimulus", "negative regulation of synaptic vesicle exocytosis", "negative regulation of endothelial cell apoptotic process" ] }, "pathway_biocarta": [ "MAPKinase Signaling Pathway" ], "pathway_consensuspathdb": [ "Non-small cell lung cancer - Homo sapiens (human)", "Chronic myeloid leukemia - Homo sapiens (human)", "Gastric cancer - Homo sapiens (human)", "Focal adhesion - Homo sapiens (human)", "mTOR signaling pathway - Homo sapiens (human)", "Renal cell carcinoma - Homo sapiens (human)", "Long-term potentiation - Homo sapiens (human)", "Neurotrophin signaling pathway - Homo sapiens (human)", "Serotonergic synapse - Homo sapiens (human)", "Melanoma - Homo sapiens (human)", "Cushing,s syndrome - Homo sapiens (human)", "Bladder cancer - Homo sapiens (human)", "Long-term depression - Homo sapiens (human)", "Acute myeloid leukemia - Homo sapiens (human)", "Breast cancer - Homo sapiens (human)", "ErbB signaling pathway - Homo sapiens (human)", "FoxO signaling pathway - Homo sapiens (human)", "Chemokine signaling pathway - Homo sapiens (human)", "Regulation of actin cytoskeleton - Homo sapiens (human)", "Hepatocellular carcinoma - Homo sapiens (human)", "Glioma - Homo sapiens (human)", "Prostate cancer - Homo sapiens (human)", "cAMP signaling pathway - Homo sapiens (human)", "Vascular smooth muscle contraction - Homo sapiens (human)", "Rap1 signaling pathway - Homo sapiens (human)", "MAPK signaling pathway - Homo sapiens (human)", "Natural killer cell mediated cytotoxicity - Homo sapiens (human)", "Proteoglycans in cancer - Homo sapiens (human)", "Pathways in cancer - Homo sapiens (human)", "Hepatitis C - Homo sapiens (human)", "Thyroid cancer - Homo sapiens (human)", "Pancreatic cancer - Homo sapiens (human)", "Endometrial cancer - Homo sapiens (human)", "Colorectal cancer - Homo sapiens (human)", "Alcoholism - Homo sapiens (human)", "Insulin signaling pathway - Homo sapiens (human)", "Progesterone-mediated oocyte maturation - Homo sapiens (human)", "Pathway_PA165959425", "Sorafenib Pharmacodynamics", "Vemurafenib Pathway, Pharmacodynamics", "update your name in edit mode", "Intracellular Signalling Through Adenosine Receptor A2b and Adenosine", "Intracellular Signalling Through Adenosine Receptor A2a and Adenosine", "EGF-Core", "Integrin-mediated Cell Adhesion", "Human Thyroid Stimulating Hormone (TSH) signaling pathway", "Signaling Pathways in Glioblastoma", "B Cell Receptor Signaling Pathway", "Corticotropin-releasing hormone signaling pathway", "Integrated Lung Cancer Pathway", "Polycystic Kidney Disease Pathway", "Bladder Cancer", "Focal Adhesion", "BDNF-TrkB Signaling", "MAPK Signaling Pathway", "Chemokine signaling pathway", "ESC Pluripotency Pathways", "Endometrial cancer", "MET in type 1 papillary renal cell carcinoma", "Chromosomal and microsatellite instability in colorectal cancer", "MAPK Cascade", "EGF-EGFR Signaling Pathway", "Regulation of Actin Cytoskeleton", "Senescence and Autophagy in Cancer", "Estrogen signaling pathway", "Serotonin HTR1 Group and FOS Pathway", "Serotonin Receptor 4-6-7 and NR3C Signaling", "Negative regulation of FGFR2 signaling", "Signaling by FGFR2", "MAP2K and MAPK activation", "RAF activation", "Disease", "Negative regulation of FGFR3 signaling", "Signaling by FGFR3", "Signal Transduction", "Negative regulation of FGFR4 signaling", "Signaling by FGFR4", "Signaling by FGFR", "Spry regulation of FGF signaling", "B cell receptor signaling", "GPCR Adenosine A2A receptor", "GPCR GroupI metabotropic glutamate receptor", "GPCR signaling-G alpha q", "CD4 T cell receptor signaling-ERK cascade", "ARMS-mediated activation", "IGF signaling", "FGF", "Negative feedback regulation of MAPK pathway", "Neuronal System", "GPCR signaling-G alpha s Epac and ERK", "Signalling to p38 via RIT and RIN", "IL-7 signaling", "GPCR signaling-G alpha s PKA and ERK", "Frs2-mediated activation", "Prolonged ERK activation events", "Signalling to ERKs", "Signaling by NTRK1 (TRKA)", "Integrin", "Signaling by NTRKs", "EGFR1", "Ras signaling in the CD4+ TCR pathway", "ErbB1 downstream signaling", "Negative regulation of MAPK pathway", "RAF/MAP kinase cascade", "MAPK1/MAPK3 signaling", "MAPK family signaling cascades", "JAK STAT pathway and regulation", "NGF", "EPO signaling", "Neurotransmitter receptors and postsynaptic signal transmission", "Transmission across Chemical Synapses", "CREB phosphorylation through the activation of Ras", "Post NMDA receptor activation events", "Activation of NMDA receptor and postsynaptic events", "Signaling by Receptor Tyrosine Kinases", "Signaling by RAS mutants", "VEGF", "Signaling by high-kinase activity BRAF mutants", "Signaling by moderate kinase activity BRAF mutants", "Paradoxical activation of RAF signaling by kinase inactive BRAF", "mTOR signaling pathway", "Signaling by BRAF and RAF fusions", "Oncogenic MAPK signaling", "Diseases of signal transduction", "CDC42 signaling events", "Downstream signaling in naï", "ve CD8+ T cells", "Signaling events mediated by focal adhesion kinase", "PDGFR-beta signaling pathway", "Trk receptor signaling mediated by the MAPK pathway", "Signaling events mediated by VEGFR1 and VEGFR2", "Negative regulation of FGFR1 signaling", "Signaling by FGFR1", "CD4 T cell receptor signaling" ], "expression_gnf_atlas": [ "pons", "ciliary ganglion", "dorsal root ganglion", "atrioventricular node", "superior cervical ganglion", "trigeminal ganglion", "testis" ], "expression_egenetics": [ "amygdala", "spleen", "liver", "stomach", "germinal center", "testis", "brain", "lung", "thyroid", "whole body", "frontal lobe", "head and neck", "placenta", "islets of Langerhans" ], "pathway_uniprot": null, "function_description": "Protein kinase involved in the transduction of mitogenic signals from the cell membrane to the nucleus. May play a role in the postsynaptic responses of hippocampal neuron. Phosphorylates MAP2K1, and thereby contributes to the MAP kinase signal transduction pathway. ", "disease_description": [ "Defects in BRAF are found in a wide range of cancers. ", "Colorectal cancer (CRC) [MIM:114500]: A complex disease characterized by malignant lesions arising from the inner wall of the large intestine (the colon) and the rectum. Genetic alterations are often associated with progression from premalignant lesion (adenoma) to invasive adenocarcinoma. Risk factors for cancer of the colon and rectum include colon polyps, long-standing ulcerative colitis, and genetic family history. ", "Lung cancer (LNCR) [MIM:211980]: A common malignancy affecting tissues of the lung. The most common form of lung cancer is non-small cell lung cancer (NSCLC) that can be divided into 3 major histologic subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung cancer. NSCLC is often diagnosed at an advanced stage and has a poor prognosis. ", "Familial non-Hodgkin lymphoma (NHL) [MIM:605027]: Cancer that starts in cells of the lymph system, which is part of the body's immune system. NHLs can occur at any age and are often marked by enlarged lymph nodes, fever and weight loss. ", "Cardiofaciocutaneous syndrome 1 (CFC1) [MIM:115150]: A multiple congenital anomaly disorder characterized by a distinctive facial appearance, heart defects and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices. ", "Noonan syndrome 7 (NS7) [MIM:613706]: A form of Noonan syndrome, a disease characterized by short stature, facial dysmorphic features such as hypertelorism, a downward eyeslant and low-set posteriorly rotated ears, and a high incidence of congenital heart defects and hypertrophic cardiomyopathy. Other features can include a short neck with webbing or redundancy of skin, deafness, motor delay, variable intellectual deficits, multiple skeletal defects, cryptorchidism, and bleeding diathesis. Individuals with Noonan syndrome are at risk of juvenile myelomonocytic leukemia, a myeloproliferative disorder characterized by excessive production of myelomonocytic cells. ", "LEOPARD syndrome 3 (LPRD3) [MIM:613707]: A disorder characterized by lentigines, electrocardiographic conduction abnormalities, ocular hypertelorism, pulmonic stenosis, abnormalities of genitalia, retardation of growth, and sensorineural deafness. ", "A chromosomal aberration involving BRAF is found in pilocytic astrocytomas. A tandem duplication of 2 Mb at 7q34 leads to the expression of a KIAA1549-BRAF fusion protein with a constitutive kinase activity and inducing cell transformation. " ], "gene_damage_prediction": { "primary_immunodeficiency": { "autosomalrecessive": "Medium", "autosomaldominant": "Medium", "all": "Medium" }, "mendelian": { "autosomalrecessive": "Medium", "autosomaldominant": "Medium", "all": "Medium" }, "cancer": { "recessive": "Medium", "dominant": "Medium", "all": "Medium" }, "all": "Medium" }, "mgi_mouse_gene": "Braf", "mgi_mouse_phenotype": [ "liver/biliary system phenotype", "respiratory system phenotype", "behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan)", "embryo phenotype", "pigmentation phenotype", "neoplasm", "hematopoietic system phenotype", "cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan)", "reproductive system phenotype", "normal phenotype", "mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span)", "vision/eye phenotype", "digestive/alimentary phenotype", "limbs/digits/tail phenotype", "nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan)", "skeleton phenotype", "renal/urinary system phenotype", "immune system phenotype", "homeostasis/metabolism phenotype", "cellular phenotype", "endocrine/exocrine gland phenotype", "adipose tissue phenotype (the observable morphological and physiological characteristics of mammalian fat tissue that are manifested through development and lifespan)", "growth/size/body region phenotype", "integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan)", "craniofacial phenotype", "muscle phenotype" ], "zfin_zebrafish_gene": null, "zfin_zebrafish_structure": null, "zfin_zebrafish_phenotype_quality": null, "zfin_zebrafish_phenotype_tag": null } ] }, "exac_genes": { "version": "18-Sep-2018", "items": [ { "prec": 0.000021804000000000003, "pnull": 3.88216e-14, "pli": 0.999978, "syn_z": -0.006721120000000002, "mis_z": 3.9913399999999997, "cnv_score": 0.5920480000000001, "segdups": 0, "flag": false } ] }, "publications": { "publications": [], "genes": [ { "publications": [ { "referenced_by": [ "VarSome AI" ], "pub_med_id": 38909266 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 38903495 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 38893159 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 38893126 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 38886866 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 38877124 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 38869029 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 38866361 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 38862695 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 38859980 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 38859602 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 38851877 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 38850505 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 38821638 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 38820929 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 38807013 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 38798959 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 38782781 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 38777950 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 38777565 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 38771344 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 38737798 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 38728872 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 38716076 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 38711893 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 38642578 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 38617091 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 38603866 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 38556167 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 38553360 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 38529368 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 38487343 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 38479107 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 38470950 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 38446982 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 38429896 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 38429142 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 38409377 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 38343359 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 38290249 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 38283732 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 38269481 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 38254847 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 38248103 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 38241570 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 38229767 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 38158377 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 38112165 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 38109210 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 38096472 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 38092180 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 38062767 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 37978284 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 37972659 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 37968472 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 37948122 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 37906695 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 37894428 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 37879236 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 37860756 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 37838724 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 37833251 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 37808191 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 37733309 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 37728240 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 37713162 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 37664946 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 37656784 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 37643378 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 37629086 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 37629011 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 37628868 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 37581616 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 37537299 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 37533438 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 37504287 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 37463056 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 37433431 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 37429463 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 37417899 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 37404765 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 37403699 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 37364232 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 37352476 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 37296851 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 37284406 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 37270692 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 37240418 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 37231247 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 37219686 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 37213293 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 37201672 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 37185420 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 37151366 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 37140883 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 37122752 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 37117198 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 37007070 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 36996322 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 36967525 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 36947734 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 36923435 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 36921494 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 36915452 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 36901951 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 36892668 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 36856908 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 36855200 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 36835466 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 36825105 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 36812376 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 36801912 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 36790480 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 36773463 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 36763936 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 36759733 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 36713531 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 36702949 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 36696464 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 36693125 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 36686670 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 36674722 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 36638198 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 36635501 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 36622773 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 36620501 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 36608320 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 36585710 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 36579983 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 36578928 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 36531075 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 36505826 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 36475784 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 36470901 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 36442478 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 36435874 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 36419902 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 36419886 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 36419139 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 36409971 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 36403965 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 36402789 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 36387226 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 36375115 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 36373817 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 36347258 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 36313893 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 36307775 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 36304179 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 36288238 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 36256645 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 36251117 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 36221356 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 36217799 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 36217175 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 36209871 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 36202073 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 36198029 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 36180314 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 36163281 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 36157689 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 36156323 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 36142267 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 36136211 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 36130145 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 36108341 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 36103644 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 36097219 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 36089135 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 36077693 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 36069292 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 36059688 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 36053834 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 36049147 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 36039514 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 36011019 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35994225 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35978838 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35978013 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35915157 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35912549 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35907983 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35904599 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35904169 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35882450 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35871080 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35862871 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35832541 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35820242 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35810049 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35778698 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35764604 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35739536 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35738942 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35728875 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35713454 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35709927 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35709404 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35705814 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35696748 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35693217 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35689405 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35687047 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35673672 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35673401 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35666229 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35658861 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35658604 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35654691 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35653981 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35644704 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35642348 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35630083 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35621684 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35598548 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35567913 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35551160 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35543076 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35524774 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35522139 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35513832 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35503983 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35494035 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35484611 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35472012 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35461050 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35456430 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35418823 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35385748 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35382161 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35378489 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35372088 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35363510 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35361262 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35350808 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35332208 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35325867 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35319964 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35319526 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35302851 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35272485 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35242981 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35231860 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35194848 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35187715 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35156519 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35154635 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35145907 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35135143 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35100697 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35085662 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35078985 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35074651 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35066105 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35050727 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35046062 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35045748 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35045286 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35042070 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35030011 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35026411 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 35022320 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 34994629 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 34994624 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 34972706 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 34969747 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 34956922 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 34918546 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 34885191 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 34843129 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 34838156 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 34820641 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 34818649 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 34804000 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 34759319 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 34742158 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 34712484 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 34687488 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 34680367 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 34680332 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 34673281 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 34671549 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 34667063 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 34655839 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 34648945 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 34635506 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 34626238 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 34625582 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 34590045 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 34588906 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 34573422 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 34573299 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 34547192 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 34541672 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 34525976 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 34504796 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 34504233 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 34476331 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 34439280 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 34433654 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 34417144 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 34416167 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 34387589 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 34376578 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 34363682 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 34337566 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 34331515 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 34330842 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 34325617 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 34322384 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 34304052 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 34301793 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 34261040 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 34250388 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 34232949 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 34225229 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 34205480 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 34201252 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 34184824 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 34178685 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 34172397 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 34167970 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 34161704 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 34148767 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 34117033 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 34108213 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 34104084 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 34091420 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 34088725 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 34083237 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 34079290 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 34069952 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 34069882 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 34064013 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 34058070 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 34057693 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 34050359 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 34026601 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 34011980 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33980169 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33979489 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33976643 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33953400 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33948387 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33947696 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33945921 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33932130 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33929516 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33917428 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33898318 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33884105 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33861486 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33855281 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33844889 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33844777 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33843879 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33843797 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33842538 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33842454 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33842329 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33842313 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33842311 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33841154 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33840166 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33839364 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33838468 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33837564 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33836681 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33836264 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33835015 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33833885 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33832365 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33827932 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33827048 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33826614 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33825902 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33824801 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33824136 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33823338 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33821796 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33820865 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33820494 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33818860 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33816227 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33813380 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33812673 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33812322 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33811161 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33811006 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33810799 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33810240 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33810045 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33808846 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33808549 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33808483 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33807876 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33807778 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33806450 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33804910 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33804800 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33804655 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33802790 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33801781 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33801689 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33799709 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33798535 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33796913 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33795873 }, { "referenced_by": [ "PanelApp", "VarSome AI" ], "pub_med_id": 33795686 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33794577 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33794385 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33794192 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33793658 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33791912 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33790328 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33789920 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33789203 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33788730 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33788170 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33788150 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33787635 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33786920 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33786064 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33785445 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33784337 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33783022 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33782564 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33781756 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33781501 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33779326 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33778733 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33778379 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33777783 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33777766 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33777735 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33777217 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33777142 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33776436 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33776257 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33774706 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33773991 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33773808 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33772213 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33771664 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33770057 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33769497 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33766816 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33766731 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33765713 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33765322 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33764743 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33763431 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33763376 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33761899 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33761808 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33761111 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33759774 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33759771 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33759769 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33759768 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33759171 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33759074 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33758144 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33753637 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33750776 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33750116 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33749950 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33749549 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33748479 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33748026 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33747896 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33747359 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33747198 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33747149 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33746966 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33746582 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33745909 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33745244 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33744168 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33743547 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33742360 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33741929 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33741812 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33739782 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33739477 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33738957 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33738444 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33738258 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33738249 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33737597 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33737510 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33737000 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33735913 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33735811 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33734441 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33734401 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33734300 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33733458 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33733342 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33732653 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33732456 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33731847 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33731665 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33731038 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33730175 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33727167 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33726891 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33726687 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33724754 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33723402 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33723350 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33723174 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33723170 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33722853 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33722842 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33722699 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33718977 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33718253 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33718241 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33716974 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33713851 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33712927 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33712303 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33712056 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33711672 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33711671 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33708984 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33708816 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33707308 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33707307 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33706781 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33706747 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33704722 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33704721 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33704186 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33692938 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33690170 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33688558 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33686791 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33686177 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33685720 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33685196 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33684943 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33684228 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33683689 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33683644 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33683500 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33682162 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33682121 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33680957 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33680376 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33678584 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33677934 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33677931 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33677887 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33676295 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33676177 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33676171 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33676017 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33675399 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33675299 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33675293 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33674596 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33672955 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33672707 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33671994 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33671989 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33670365 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33669949 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33669856 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33669326 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33668025 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33667718 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33664427 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33664195 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33663128 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33659200 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33657824 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33657282 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33656790 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33654307 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33653716 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33653337 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33651913 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33651322 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33651321 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33650659 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33649790 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33649458 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33647816 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33647741 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33647496 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33647348 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33646525 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33644840 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33643536 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33641074 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33641072 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33637608 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33637515 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33636938 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33636398 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33635624 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33635598 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33635116 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33633989 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33633980 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33632774 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33632153 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33631225 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33631044 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33631043 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33630242 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33628737 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33627164 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33626378 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33625103 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33624271 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33623106 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33622273 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33619394 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33619118 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33618249 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33618199 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33618198 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33618059 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33617147 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33613844 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33613767 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33612324 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33611888 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33611636 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33611593 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33610860 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33610559 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33610156 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33608382 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33604667 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33603403 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33602512 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33602172 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33602153 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33602034 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33601311 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33600004 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33599905 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33599171 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33599007 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33598819 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33595872 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33591844 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33591350 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33587894 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33587356 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33586907 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33585210 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33583086 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33582932 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33582915 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33582427 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33580200 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33580193 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33579816 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33579557 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33578810 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33578751 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33578538 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33577183 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33576854 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33574947 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33574927 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33574842 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33574795 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33574103 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33574086 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33572972 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33572167 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33569997 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33569738 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33569513 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33569345 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33568647 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33568355 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33565241 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33563994 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33562578 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33562484 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33562468 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33562337 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33560788 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33560745 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33559224 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33558987 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33558722 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33557890 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33557011 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33556898 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33556087 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33555543 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33555379 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33555095 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33552685 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33552663 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33551379 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33551244 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33551196 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33551126 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33551068 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33550925 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33549048 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33548159 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33547983 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33547199 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33547013 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33546249 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33545343 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33543394 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33543377 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33543147 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33539032 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33537843 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33535609 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33535453 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33535416 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33534128 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33530623 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33530579 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33530327 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33529639 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33527115 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33526881 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33526222 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33525803 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33524004 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33522711 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33522658 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33522492 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33515759 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33513356 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33509808 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33507915 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33507258 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33506327 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33506199 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33504544 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33504438 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33504219 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33503876 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33503528 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33503394 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33503393 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33500549 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33500359 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33500258 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33499262 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33498757 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33497736 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33495600 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33495189 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33494131 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33493149 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33493146 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33491923 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33490154 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33489866 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33484192 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33483600 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33483342 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33482860 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33482532 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33478735 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33478436 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33478196 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33478186 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33478111 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33476722 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33476492 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33474634 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33472910 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33470132 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33469997 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33469503 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33469371 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33469107 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33468909 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33468842 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33468157 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33467521 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33466206 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33465286 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33464748 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33464119 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33461766 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33456727 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33455693 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33455008 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33454506 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33452985 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33452216 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33451139 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33451059 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33448717 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33448329 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33448230 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33447541 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33446566 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33446148 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33444485 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33444290 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33443864 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33443847 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33443622 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33442661 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33442367 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33441414 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33441391 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33441310 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33441131 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33440616 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33440231 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33439966 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33438848 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33437479 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33437383 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33436306 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33435440 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33435234 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33435133 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33433883 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33433598 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33431809 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33430710 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33429770 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33428730 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33428337 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33428294 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33426601 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33425097 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33423919 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33420213 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33419898 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33419372 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33419275 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33415015 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33414915 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33414407 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33414136 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33414052 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33413831 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33413689 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33413561 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33413175 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33408093 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33407743 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33407577 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33406789 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33406649 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33405774 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33403024 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33403009 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33402480 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33402199 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33401991 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33400370 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33400355 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33399314 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33399091 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33398670 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33398196 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33396957 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33396645 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33396632 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33395399 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33395033 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33394641 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33392769 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33392503 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33392197 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33392186 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33391380 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33389859 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33389388 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33389075 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33387732 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33387125 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33387037 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33385518 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33383664 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33383577 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33383207 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33382428 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33382403 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33382354 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33382132 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33381330 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33380804 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33380672 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33377602 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33377543 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33376356 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33375360 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33375029 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33373869 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33373866 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33373127 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33372104 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33371755 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33371382 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33370253 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33370037 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33368279 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33368052 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33367512 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33364820 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33364070 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33363952 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33362182 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33362181 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33361337 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33360690 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33358484 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33356500 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33356422 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33355204 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33355187 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33351968 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33351553 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33351322 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33346834 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33344292 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33344274 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33341703 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33341444 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33339135 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33338202 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33337839 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33336844 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33336421 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33336394 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33335731 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33335401 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33334695 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33332664 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33332330 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33331169 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33330635 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33330555 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33330092 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33330081 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33330032 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33328743 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33327495 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33327482 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33327467 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33327228 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33325154 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33324955 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33324104 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33321462 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33321086 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33318795 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33318584 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33318037 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33317812 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33317591 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33316486 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33316418 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33315986 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33315631 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33314759 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33314633 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33314422 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33313992 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33313671 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33312889 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33312171 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33309774 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33309473 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33306619 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33306107 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33305912 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33305870 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33305405 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33305271 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33304455 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33303574 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33300554 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33300106 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33299862 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33299797 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33299111 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33297669 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33297339 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33296098 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33295826 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33295742 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33293828 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33292371 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33288749 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33285519 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33284613 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33283554 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33282733 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33282585 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33280830 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33279248 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33278771 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33277344 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33276639 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33276219 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33275721 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33275172 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33274568 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33273059 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33272718 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33271567 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33269152 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33268358 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33266349 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33266265 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33262833 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33261504 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33260923 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33260892 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33259900 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33258947 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33258245 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33258138 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33256240 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33255659 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33255238 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33254249 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33252666 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33252399 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33252274 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33250740 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33250739 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33250737 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33249657 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33249369 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33249201 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33248711 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33247684 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33247675 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33245930 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33245464 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33242360 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33241586 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33241217 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33240806 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33238958 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33238942 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33238621 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33238500 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33238129 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33237469 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33237284 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33235471 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33235460 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33235141 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33234846 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33234845 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33232779 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33231757 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33230914 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33230747 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33230298 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33229534 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33229221 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33228740 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33227796 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33227559 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33225752 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33224863 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33224862 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33224861 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33224854 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33224845 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33224365 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33224274 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33222100 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33219618 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33219484 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33219056 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33216832 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33216826 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33216057 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33215864 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33214457 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33213339 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33211390 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33211315 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33210922 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33210886 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33210163 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33209599 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33208919 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33208845 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33208016 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33207206 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33206716 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33205710 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33205306 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33204897 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33204026 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33203961 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33203734 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33203662 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33203645 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33202944 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33202284 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33201161 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33199152 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33198784 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33198372 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33197299 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33195668 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33195430 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33194656 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33193858 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33191640 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33191401 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33190264 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33189037 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33188936 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33185331 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33184347 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33183728 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33183426 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33179310 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33178757 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33178750 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33178599 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33178341 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33178273 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33176823 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33175991 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33175216 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33175195 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33170593 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33169510 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33166576 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33165713 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33165348 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33162943 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33162496 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33162442 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33161228 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33160715 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33159968 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33156595 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33156594 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33154303 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33153497 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33152998 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33152822 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33152817 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33152763 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33152307 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33152306 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33151472 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33151462 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33151122 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33150263 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33149691 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33148693 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33145020 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33144428 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33144396 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33143568 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33143299 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33142243 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33139839 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33138697 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33135196 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33134923 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33133378 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33132786 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33128316 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33127831 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33127167 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33123389 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33122997 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33122747 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33122628 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33122190 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33120998 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33120354 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33119140 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33119105 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33118306 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33117686 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33117675 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33116365 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33116270 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33115802 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33115526 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33113355 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33113092 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33110363 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33109619 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33108877 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33107799 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33107403 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33105692 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33102773 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33102215 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33101670 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33100226 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33099543 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33099304 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33095329 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33092982 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33092905 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33091816 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33090333 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33089815 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33089615 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33088794 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33088346 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33087895 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33087330 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33086655 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33085976 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33085557 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33084582 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33084375 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33082744 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33082316 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33082211 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33081201 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33081092 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33080011 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33079606 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33078187 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33077847 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33076847 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33075161 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33073191 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33072607 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33071276 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33071274 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33070910 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33070899 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33069191 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33068418 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33067256 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33067182 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33066758 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33064882 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33064665 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33063902 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33063010 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33061436 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33060766 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33060170 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33058026 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33054840 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33053749 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33053439 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33052631 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33052075 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33050344 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33049752 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33048248 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33048186 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33047672 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33046979 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33046726 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33046519 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33046448 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33046237 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33046021 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33045465 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33045146 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33044751 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33044631 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33043759 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33043255 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33043062 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33042847 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33042833 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33041225 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33040839 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33040082 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33039558 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33038627 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33038084 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33037234 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33036192 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33036022 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33035332 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33034420 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33034230 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33033678 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33032379 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33031392 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33031197 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33031052 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33030957 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33030382 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33030125 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33030071 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33029242 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33028762 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33028695 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33027050 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33026636 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33024276 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33020648 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33020646 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33019809 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33019710 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33015528 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33015526 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33015265 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33014862 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33014052 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33012489 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33012268 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33009979 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33009870 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33007433 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33007097 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33005620 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33005299 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33004975 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33003483 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33003444 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33002893 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 33000894 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32999736 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32997575 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32996219 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32995956 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32993393 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32991441 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32991018 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32990852 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32989499 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32989488 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32989177 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32988996 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32987287 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32985015 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32984984 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32984045 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32982400 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32981611 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32980422 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32980421 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32978897 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32978468 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32976686 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32974694 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32973641 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32973134 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32972866 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32971203 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32970929 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32970425 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32970096 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32968045 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32967672 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32966885 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32966782 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32966350 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32966238 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32965665 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32965631 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32964533 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32962182 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32961530 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32961317 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32957012 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32956754 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32956080 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32954834 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32953608 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32953605 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32953595 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32953516 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32951896 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32951290 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32950263 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32948319 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32948110 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32948083 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32948031 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32947841 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32947221 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32946353 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32946312 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32945606 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32945494 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32945109 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32944951 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32943104 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32942199 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32940914 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32939809 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32938808 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32938713 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32936899 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32935463 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32933538 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32932925 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32932803 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32932758 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32932213 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32930721 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32930446 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32930397 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32929178 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32928833 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32927517 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32927473 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32926988 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32923935 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32923934 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32923904 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32923898 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32923882 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32923867 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32923395 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32923312 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32922664 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32922659 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32921581 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32920709 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32920363 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32918774 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32918169 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32916163 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32915318 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32915145 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32915106 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32914373 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32914034 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32914028 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32914022 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32914018 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32914004 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32913995 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32913992 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32913989 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32913986 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32913971 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32913556 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32913191 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32912923 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32910905 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32910840 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32910224 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32910018 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32907612 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32907530 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32907318 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32899322 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32899183 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32898554 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32898395 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32898388 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32898185 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32896487 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32896119 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32895045 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32894202 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32893700 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32893164 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32892557 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32892555 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32890629 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32889896 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32889679 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32889387 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32888955 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32888274 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32887776 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32884102 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32883742 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32881280 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32881028 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32880495 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32879641 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32878554 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32878000 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32877599 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32875931 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32875553 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32875153 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32873927 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32873792 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32873703 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32873617 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32873393 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32872561 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32871287 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32871054 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32869334 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32868647 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32868527 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32867715 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32866902 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32866426 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32863956 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32863071 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32862732 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32861617 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32861208 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32859654 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32859279 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32859224 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32858795 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32858564 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32858528 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32857940 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32857459 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32853962 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32853767 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32850962 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32850378 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32850329 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32848419 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32847629 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32846030 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32844293 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32843902 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32843432 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32843426 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32839179 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32836055 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32831310 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32830166 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32827026 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32826083 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32825973 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32825554 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32825510 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32825275 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32822286 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32821296 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32821295 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32821125 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32820496 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32820016 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32818466 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32817175 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32817137 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32816852 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32816630 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32816325 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32815816 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32815691 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32815004 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32814079 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32813205 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32812852 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32811569 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32810930 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32810748 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32809978 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32806531 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32804914 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32804454 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32804453 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32803788 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32802728 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32802170 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32801341 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32801082 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32800272 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32800052 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32799717 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32798016 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32797121 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32796636 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32793120 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32792685 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32792599 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32792597 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32791233 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32790489 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32788236 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32786457 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32785802 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32785740 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32784934 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32784823 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32784465 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32784332 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32783159 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32782671 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32782545 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32782486 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32781560 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32780261 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32778845 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32777214 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32776753 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32776443 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32776349 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32775409 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32774506 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32774277 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32774248 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32774165 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32773458 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32773008 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32772211 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32771948 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32771057 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32770529 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32770176 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32769548 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32768704 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32765888 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32765790 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32765066 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32764384 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32763518 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32762307 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32761808 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32761749 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32761642 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32761153 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32760738 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32759235 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32758030 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32757402 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32757330 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32756609 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32756468 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32755147 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32754440 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32753547 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32751594 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32751423 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32751207 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32751138 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32750720 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32750121 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32748173 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32747568 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32747372 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32746839 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32744692 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32743766 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32741580 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32740981 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32739935 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32739910 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32738155 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32737449 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32737003 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32736279 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32736188 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32734632 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32734128 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32731406 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32731184 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32730814 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32729257 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32726988 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32726404 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32722474 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32722429 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32722188 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32720533 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32720348 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32720072 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32719131 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32718285 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32718103 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32718045 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32715806 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32714871 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32714544 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32713220 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32712959 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32708687 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32708268 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32707252 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32705137 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32703500 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32703499 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32702928 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32701378 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32700768 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32700762 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32700475 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32700043 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32699976 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32699571 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32698386 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32698374 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32697281 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32697051 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32696585 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32695793 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32693944 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32692912 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32691644 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32689779 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32687679 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32686704 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32685785 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32684057 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32684022 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32682884 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32682222 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32681943 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32681762 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32681754 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32679231 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32677947 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32675393 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32674932 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32673997 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32672795 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32671986 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32671901 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32671117 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32670650 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32669928 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32669376 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32669268 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32668867 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32667719 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32667249 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32667108 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32666385 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32666260 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32665851 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32665850 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32665205 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32664549 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32663310 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32661852 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32661416 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32661327 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32658050 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32657876 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32657049 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32656925 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32656857 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32654197 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32654047 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32653217 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32652567 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32651027 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32650968 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32649344 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32648858 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32648137 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32648041 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32647535 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32646966 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32646931 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32646613 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32645997 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32645969 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32643344 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32642996 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32642735 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32642725 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32642724 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32642685 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32642495 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32640856 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32639612 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32638211 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32638206 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32637584 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32637031 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32635826 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32634771 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32633344 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32632950 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32632141 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32631434 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32629543 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32629178 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32628708 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32627883 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32626712 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32625092 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32621051 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32620917 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32620791 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32620519 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32619504 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32619305 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32615728 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32614358 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32613561 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32612709 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32612457 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32610387 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32609833 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32609446 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32607694 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32606919 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32606114 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32605662 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32605254 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32605090 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32604720 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32604167 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32602215 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32602174 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32601947 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32601132 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32600657 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32600223 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32598268 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32597321 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32596667 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32595468 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32594366 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32594172 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32593310 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32591993 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32591646 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32590884 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32590338 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32589764 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32588244 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32585901 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32583303 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32581559 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32581551 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32581366 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32581248 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32581042 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32580578 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32580537 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32580351 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32580246 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32579928 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32578014 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32575941 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32575838 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32575591 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32574135 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32572821 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32571791 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32571131 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32568833 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32562975 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32562448 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32561850 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32561648 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32560331 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32559584 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32558291 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32556513 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32556494 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32555626 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32554314 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32554313 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32553612 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32553555 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32553158 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32552173 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32552041 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32547201 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32547066 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32546576 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32546168 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32545884 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32544965 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32542563 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32541157 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32540454 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32540409 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32539314 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32535664 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32535222 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32534795 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32534646 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32534635 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32534242 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32532957 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32532044 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32531927 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32531202 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32530992 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32530551 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32529787 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32529280 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32528879 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32528726 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32527755 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32527614 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32527075 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32526884 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32526042 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32525942 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32525522 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32523649 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32522509 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32521388 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32519179 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32517177 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32515090 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32515086 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32515012 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32514929 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32514165 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32509076 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32507810 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32507497 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32506424 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32506370 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32504402 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32504335 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32503946 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32502983 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32501726 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32499221 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32498251 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32495721 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32495172 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32495162 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32495109 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32494745 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32493700 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32493394 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32487991 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32486540 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32485528 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32484959 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32483596 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32483558 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32483240 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32483191 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32482319 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32481659 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32481270 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32478079 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32477956 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32477915 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32477464 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32477420 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32476450 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32476297 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32476174 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32476062 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32474402 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32470910 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32470760 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32467529 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32466770 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32466585 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32466509 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32466217 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32463489 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32462837 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32462295 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32462249 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32458259 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32455924 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32455577 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32455336 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32454006 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32452220 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32451331 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32450595 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32450593 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32449784 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32449085 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32449003 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32447786 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32447656 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32447231 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32444628 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32444378 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32441866 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32441577 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32441371 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32440157 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32432164 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32429639 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32428838 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32428249 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32427961 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32427409 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32427204 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32426287 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32425887 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32423455 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32422543 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32420017 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32418154 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32418051 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32415973 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32415114 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32414111 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32413973 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32413929 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32413516 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32411601 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32411236 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32411231 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32410160 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32408300 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32408133 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32406600 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32405640 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32404956 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32404732 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32403192 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32402656 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32402358 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32401131 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32399739 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32399637 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32399264 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32399011 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32397295 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32394048 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32393797 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32393293 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32393282 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32392931 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32392832 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32392586 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32391110 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32390600 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32388775 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32388526 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32388065 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32387454 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32387453 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32386465 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32386297 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32386112 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32385709 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32385563 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32385388 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32384877 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32384699 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32384640 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32384323 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32382835 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32382617 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32382005 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32381551 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32381353 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32380762 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32380013 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32378970 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32378072 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32377829 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32377702 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32376853 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32376722 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32376279 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32376239 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32373528 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32373219 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32372223 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32371878 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32371339 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32370213 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32369821 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32368535 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32368388 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32368160 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32367668 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32366411 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32366406 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32365867 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32365229 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32364948 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32364844 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32362631 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32361034 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32358715 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32358694 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32358589 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32357967 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32357861 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32357308 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32355756 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32351906 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32351561 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32350854 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32350685 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32350628 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32348888 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32348852 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32347351 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32346875 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32346746 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32346533 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32345963 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32345726 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32345725 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32345648 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32345593 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32344898 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32343143 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32341768 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32337758 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32336065 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32335325 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32334110 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32334103 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32333269 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32333141 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32330348 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32330187 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32328470 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32328381 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32328187 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32326836 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32326305 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32325863 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32323422 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32323012 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32321884 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32321716 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32321474 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32321411 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32319656 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32319586 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32319330 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32319011 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32318348 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32317300 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32316638 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32315324 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32315234 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32314268 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32314157 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32313769 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32313236 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32311241 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32308588 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32308090 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32306207 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32305313 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32305056 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32304411 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32301010 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32297439 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32297204 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32297104 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32294981 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32294880 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32293049 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32291779 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32291725 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32291710 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32291398 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32291316 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32290742 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32290374 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32290033 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32285732 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32285462 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32284750 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32284020 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32283865 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32283823 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32283529 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32281047 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32278676 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32275934 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32275681 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32273508 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32273491 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32273478 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32273401 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32273326 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32271498 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32271487 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32270416 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32269717 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32269691 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32269611 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32269299 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32269290 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32269074 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32268150 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32267108 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32266211 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32265839 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32264863 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32260561 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32258485 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32257795 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32256810 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32256484 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32253677 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32253230 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32253228 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32253111 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32252664 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32252028 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32250254 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32249628 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32249344 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32248296 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32245453 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32243282 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32242226 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32241802 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32241213 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32240105 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32239892 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32239677 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32238877 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32238401 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32238382 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32236923 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32236858 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32236636 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32236609 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32236593 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32235165 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32234759 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32231814 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32231448 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32231291 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32231230 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32231083 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32228694 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32228358 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32228152 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32227635 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32227455 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32227276 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32225169 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32223367 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32223235 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32223184 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32222462 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32222087 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32221131 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32221017 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32219049 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32218819 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32218667 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32216548 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32216031 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32213878 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32213552 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32212266 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32211316 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32210264 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32209185 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32209086 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32208873 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32208298 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32207565 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32206360 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32206092 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32205440 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32204733 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32203843 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32202540 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32201826 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32198651 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32198650 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32196952 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32194748 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32194039 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32193712 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32193591 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32193459 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32190469 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32188904 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32188714 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32188503 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32187898 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32187423 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32187362 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32186929 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32185127 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32185055 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32184420 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32184228 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32183342 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32183295 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32182156 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32181767 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32181531 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32179991 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32179513 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32179447 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32178301 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32173467 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32172642 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32172334 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32171892 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32171112 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32168325 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32168263 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32167264 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32166754 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32164324 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32163911 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32162812 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32162306 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32162034 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32161617 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32158963 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32158480 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32157241 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32157211 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32156782 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32155032 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32151517 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32151273 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32150939 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32150778 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32150095 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32149725 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32146818 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32146654 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32144301 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32143579 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32143442 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32142958 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32139876 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32139260 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32132867 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32132651 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32132305 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32132106 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32131760 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32130701 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32129900 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32127259 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32126562 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32125175 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32124332 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32123804 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32123303 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32122255 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32118628 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32117703 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32114263 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32111612 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32110651 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32110210 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32108276 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32107533 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32106306 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32101678 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32101677 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32101676 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32101675 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32100878 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32100585 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32100259 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32099073 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32098826 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32098655 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32098550 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32098410 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32097280 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32097116 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32096885 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32096304 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32095377 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32095167 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32093855 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32093631 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32092958 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32092141 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32092099 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32090065 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32089414 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32088204 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32087759 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32087721 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32087194 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32085892 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32085796 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32085741 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32083567 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32083398 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32083130 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32082673 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32082488 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32079522 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32079019 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32077113 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32075397 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32074736 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32073511 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32073317 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32070090 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32069380 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32069373 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32067683 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32067622 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32066856 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32066648 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32066410 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32064677 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32063108 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32062727 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32062691 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32061302 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32061158 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32061008 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32059731 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32059462 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32059434 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32059187 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32056516 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32056395 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32056293 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32056262 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32056038 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32055496 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32054005 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32053287 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32053122 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32052681 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32052529 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32052049 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32049008 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32047535 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32047231 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32047001 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32046241 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32046148 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32045431 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32043900 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32043788 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32043781 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32043779 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32043767 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32043616 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32040962 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32040482 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32038479 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32037654 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32036084 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32034196 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32034077 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32034076 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32034073 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32031330 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32030784 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32030746 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32030223 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32029534 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32028967 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32027303 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32027186 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32026770 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32026754 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32024680 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32024448 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32021565 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32021277 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32020654 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32020479 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32020225 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32017841 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32017063 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32016676 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32016085 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32015976 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32015690 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32015513 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32012328 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32011515 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32010589 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32009180 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32007245 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32007138 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32005716 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32004563 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32003530 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32003263 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32002403 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32000721 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32000640 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32000400 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 32000215 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31998653 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31998419 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31998317 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31996097 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31995621 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31994851 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31994201 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31993771 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31991166 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31989260 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31989247 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31988522 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31988198 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31987674 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31986557 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31985841 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31985580 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31983699 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31983154 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31983090 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31982351 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31980996 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31980175 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31976506 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31976308 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31974819 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31974262 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31972251 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31970877 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31970865 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31969234 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31966927 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31966836 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31966754 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31966738 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31966606 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31966475 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31965621 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31965542 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31963890 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31963551 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31961828 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31961147 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31959346 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31959343 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31956087 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31954497 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31954088 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31953992 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31953036 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31952674 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31952366 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31952290 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31951562 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31951530 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31950824 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31950578 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31950179 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31949927 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31949805 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31949745 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31949695 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31949686 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31949594 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31949590 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31949496 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31949492 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31945494 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31945347 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31943527 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31943160 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31941461 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31940493 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31940389 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31940202 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31939681 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31938823 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31938404 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31938368 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31938267 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31937902 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31937621 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31936151 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31935792 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31935636 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31934195 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31933927 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31933925 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31933775 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31933021 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31932945 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31932756 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31930640 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31929988 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31929109 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31928887 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31927392 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31926773 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31925410 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31924735 }, { "referenced_by": [ "VarSome AI", "CIViC" ], "pub_med_id": 31924734 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31924107 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31922963 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31922436 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31922331 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31921863 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31921336 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31920193 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31920132 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31919461 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31919458 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31918469 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31918249 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31917616 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31917173 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31917154 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31915977 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31915016 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31914530 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31912793 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31912791 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31912789 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31911848 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31911617 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31911548 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31911540 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31911278 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31908303 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31906480 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31906302 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31904908 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31903803 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31903645 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31902686 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31901705 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31900433 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31899815 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31898851 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31898183 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31897467 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31897179 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31895752 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31895121 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31892193 }, { "referenced_by": [ "PanelApp", "VarSome AI" ], "pub_med_id": 31891627 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31891422 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31891418 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31890457 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31890008 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31886081 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31885734 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31883527 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31882684 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31882511 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31882020 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31881853 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31881643 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31880318 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31880125 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31877948 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31877737 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31877318 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31876604 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31876585 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31876308 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31875997 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31875302 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31874374 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31872454 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31872418 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31871776 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31871620 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31869749 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31869447 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31869246 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31867335 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31866944 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31866097 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31866016 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31865250 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31864178 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31863650 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31862522 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31862477 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31861874 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31859449 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31859066 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31857724 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31856410 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31855953 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31853887 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31853669 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31852831 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31852719 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31850129 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31848942 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31848314 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31848189 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31846216 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31844050 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31843682 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31842975 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31842958 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31841566 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31841105 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31840683 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31839880 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31839773 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31839677 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31839532 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31837432 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31836957 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31836388 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31836141 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31835364 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31835042 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31833955 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31833840 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31833658 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31833094 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31831554 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31826932 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31826931 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31824282 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31822998 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31822380 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31821747 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31821746 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31821518 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31820133 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31819973 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31819705 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31819518 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31819496 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31819183 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31818130 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31817947 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31817643 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31817473 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31817189 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31811783 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31811566 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31811196 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31811016 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31810919 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31810221 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31809326 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31807955 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31807490 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31807308 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31807276 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31806714 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31806640 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31805975 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31805304 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31804158 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31804055 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31803366 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31801793 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31801652 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31801187 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31799491 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31798981 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31798692 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31796433 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31796130 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31794934 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31793986 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31793361 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31792356 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31792037 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31791701 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31790974 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31790307 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31789933 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31786838 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31785018 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31784758 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31784493 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31784187 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31783660 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31783291 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31782259 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31781502 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31781475 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31781034 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31780644 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31777465 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31775759 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31775437 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31774904 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31774543 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31773354 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31770330 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31769426 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31769353 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31769323 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31768772 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31768714 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31768065 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31767937 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31766881 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31766556 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31765065 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31762942 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31762821 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31762713 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31759368 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31759151 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31758670 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31758648 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31758408 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31758407 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31757377 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31756131 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31755465 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31755464 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31755463 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31754963 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31753111 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31752122 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31750971 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31750751 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31748891 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31748352 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31748345 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31747798 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31747763 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31747139 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31745173 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31745079 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31744895 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31744894 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31744229 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31743128 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31741910 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31741065 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31740808 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31737634 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31737568 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31736196 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31735291 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31732523 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31731495 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31731482 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31731200 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31730502 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31728128 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31727958 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31727888 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31727009 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31726389 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31724970 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31723142 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31721725 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31719050 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31717544 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31717455 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31717363 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31715422 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31712784 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31711486 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31711466 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31711449 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31710489 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31709422 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31709194 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31708414 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31708372 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31707688 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31705876 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31705737 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31705176 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31704871 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31704811 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31704549 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31704364 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31703344 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31702822 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31700806 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31699993 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31699882 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31699039 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31698328 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31692513 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31690257 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31688243 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31687241 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31685033 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31683701 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31678973 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31677487 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31677253 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31677187 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31677173 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31676590 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31676589 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31675726 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31675434 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31673897 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31673240 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31672856 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31672771 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31672298 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31672296 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31672130 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31671409 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31668133 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31667761 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31667545 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31666933 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31666812 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31664962 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31664762 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31663661 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31663466 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31662533 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31661924 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31661699 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31661070 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31659388 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31659259 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31658370 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31658048 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31658042 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31656314 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31655998 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31655118 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31654433 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31653970 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31653608 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31653137 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31653096 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31649724 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31649038 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31649010 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31647501 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31646741 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31645901 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31645440 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31642744 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31642677 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31642023 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31641949 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31641627 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31641417 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31641034 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31640894 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31639786 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31639630 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31639332 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31637953 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31636305 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31635389 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31634988 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31634214 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31634180 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31633039 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31630873 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31630459 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31628266 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31627930 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31627522 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31627222 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31625469 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31624899 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31623671 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31623125 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31622618 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31619231 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31618797 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31618628 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31617914 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31615350 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31615127 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31614962 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31614548 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31612562 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31611963 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31610268 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31609810 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31609094 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31607543 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31606990 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31605799 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31605168 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31605106 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31602389 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31602313 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31602213 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31601986 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31601357 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31598903 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31597857 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31597339 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31596728 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31596166 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31595628 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31595523 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31594749 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31594564 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31594446 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31593036 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31592535 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31592429 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31591741 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31589789 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31587511 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31587152 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31586713 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31586312 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31585936 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31585718 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31585412 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31583878 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31583329 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31582631 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31582381 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31581559 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31581557 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31581483 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31581267 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31581174 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31580832 }, { "referenced_by": [ "VarSome AI", "CIViC" ], "pub_med_id": 31580757 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31578932 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31578731 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31578454 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31577130 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31576556 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31573152 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31571972 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31571292 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31571151 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31571052 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31570905 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31569065 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31567589 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31567539 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31567189 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31566309 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31566049 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31565873 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31563816 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31562743 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31562035 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31560489 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31560259 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31559120 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31558800 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31558799 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31558784 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31558473 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31558239 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31558234 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31557826 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31557757 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31556191 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31555967 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31555583 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31554629 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31553708 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31552251 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31551170 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31548830 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31548614 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31548566 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31547956 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31547367 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31546071 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31545494 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31545405 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31545109 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31543246 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31541850 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31541179 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31540406 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31539295 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31538800 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31538423 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31538107 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31535562 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31534501 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31534204 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31533501 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31533238 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31533235 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31532708 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31532537 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31531096 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31530880 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31530409 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31529566 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31529211 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31527903 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31527616 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31527224 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31527213 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31526463 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31520766 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31519714 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31519698 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31518489 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31517642 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31516745 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31515514 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31515463 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31515458 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31514399 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31514305 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31513482 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31506424 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31506385 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31506288 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31505115 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31505033 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31504796 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31504112 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31503397 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31503031 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31502413 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31502118 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31502039 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31500586 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31500431 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31500314 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31498175 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31497359 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31496327 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31495599 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31495087 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31493178 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31492087 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31490286 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31490234 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31489255 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31488221 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31488153 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31487245 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31484615 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31483883 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31482959 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31482953 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31482595 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31482523 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31481581 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31480291 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31478162 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31475312 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31475100 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31474758 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31473937 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31473636 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31472323 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31471937 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31470866 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31469305 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31469053 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31467489 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31467182 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31466300 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31464610 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31456414 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31455351 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31455117 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31455041 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31454788 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31454018 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31453322 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31452778 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31452772 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31452510 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31452501 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31452453 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31452441 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31450901 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31449665 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31449064 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31447330 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31446140 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31446019 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31443844 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31443496 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31443309 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31442917 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31442328 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31441596 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31441082 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31440100 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31440061 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31439678 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31439588 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31439581 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31439567 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31437754 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31437520 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31435988 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31435663 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31435661 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31434983 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31434450 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31433498 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31433323 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31432325 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31427603 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31426694 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31426590 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31426419 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31425480 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31421186 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31419753 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31418658 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31418082 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31418045 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31417840 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31417495 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31417188 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31416844 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31416288 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31416192 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31415669 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31414729 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31414376 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31413858 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31412814 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31412611 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31412566 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31412230 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31412228 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31409873 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31408190 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31407636 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31406976 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31406255 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31404694 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31404377 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31403745 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31402426 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31401373 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31401046 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31400926 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31399133 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31398831 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31397860 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31397529 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31397438 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31397092 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31396346 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31395751 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31393083 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31392064 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31392061 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31392055 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31391125 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31391014 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31388978 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31387567 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31386689 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31386297 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31386091 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31386052 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31385109 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31383965 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31383874 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31382929 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31382039 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31381132 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31379943 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31379741 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31377969 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31377847 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31376303 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31376203 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31375911 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31375769 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31375570 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31375515 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31374895 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31371335 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31369091 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31367588 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31367539 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31367274 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31364890 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31363167 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31363003 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31362929 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31362075 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31361915 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31361613 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31359162 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31358956 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31355086 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31355065 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31354355 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31354304 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31353365 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31352904 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31352611 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31351087 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31350822 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31350557 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31350469 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31348978 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31348273 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31348136 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31347092 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31346129 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31345627 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31345592 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31345255 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31344983 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31343420 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31341365 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31340860 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31340858 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31340823 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31339850 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31338879 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31338668 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31336679 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31336229 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31333799 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31331345 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31330830 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31330487 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31329636 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31329344 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31327245 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31327112 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31327063 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31324877 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31324814 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31323160 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31322645 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31321520 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31320995 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31320401 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31320305 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31319984 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31319569 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31318566 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31317326 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31317311 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31317190 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31317143 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31316083 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31314136 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31312411 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31312391 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31310691 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31308798 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31308077 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31307243 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31306728 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31306113 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31305897 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31305422 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31305421 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31305324 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31302970 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31302615 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31302002 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31300997 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31300059 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31300044 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31297240 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31296605 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31296182 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31293989 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31293647 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31292272 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31290252 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31289571 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31289333 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31287861 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31285953 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31285773 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31284081 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31282776 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31282116 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31281485 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31281144 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31281037 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31280615 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31279594 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31279529 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31277584 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31277524 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31276506 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31276098 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31274706 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31274625 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31273629 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31273418 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31271515 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31271447 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31270717 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31270153 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31269460 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31269413 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31269229 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31267558 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31267021 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31266962 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31265865 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31265477 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31263031 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31262927 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31262747 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31261448 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31261023 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31260421 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31260118 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31258847 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31258736 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31257748 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31257073 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31255173 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31254135 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31253871 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31253656 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31252408 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31252305 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31251472 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31250402 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31249721 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31247083 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31246727 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31244912 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31244646 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31243962 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31243121 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31243107 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31242703 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31242070 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31242043 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31241559 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31240514 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31239316 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31239162 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31237002 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31236710 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31235483 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31234388 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31231568 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31231466 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31231460 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31231022 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31230502 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31230400 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31229894 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31229654 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31229486 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31228537 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31227518 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31227516 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31227255 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31227006 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31226844 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31223037 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31222109 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31221662 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31221619 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31221175 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31220884 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31220642 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31219974 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31219603 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31218776 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31217909 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31217294 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31216832 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31214915 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31213829 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31213532 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31213499 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31213430 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31213260 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31212879 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31212295 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31212163 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31211467 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31209841 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31209667 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31209665 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31207212 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31205706 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31205512 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31205506 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31205066 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31204011 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31203679 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31202602 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31200827 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31200767 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31200439 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31200374 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31199922 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31199580 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31199501 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31196969 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31196660 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31192863 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31191017 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31190430 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31187521 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31186280 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31185985 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31185226 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31183866 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31183639 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31183211 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31182949 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31181803 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31181609 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31181537 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31180164 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31179560 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31177507 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31177122 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31175136 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31174179 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31173962 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31172191 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31171879 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31171878 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31171876 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31171444 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31167915 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31167268 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31166947 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31166680 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31165342 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31162857 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31161615 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31160710 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31158302 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31158244 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31157772 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31157737 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31157687 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31157261 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31152596 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31152574 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31152546 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31152084 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31152052 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31151904 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31151782 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31151362 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31149479 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31149457 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31149267 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31149206 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31148369 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31147232 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31147230 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31146260 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31142054 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31139561 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31139472 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31138295 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31136360 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31135104 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31135058 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31134762 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31132355 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31130830 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31128050 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31127889 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31126298 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31125963 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31125062 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31124185 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31123453 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31123282 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31122752 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31120137 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31119053 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31119052 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31117039 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31117032 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31116162 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31115969 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31115724 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31115206 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31114933 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31114383 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31112348 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31111538 }, { "referenced_by": [ "PanelApp", "VarSome AI" ], "pub_med_id": 31111470 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31109650 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31109165 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31108244 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31105942 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31102256 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31102091 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31101498 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31099689 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31097454 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31097263 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31096937 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31096734 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31096111 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31096110 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31095039 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31095038 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31094930 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31094496 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31093689 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31093395 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31093278 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31092613 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31092612 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31090813 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31087282 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31085957 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31085772 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31085763 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31083627 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31082912 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31082388 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31081213 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31077681 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31077629 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31077558 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31077238 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31076580 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31073511 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31072595 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31072207 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31070306 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31070037 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31068650 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31068348 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31068044 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31066955 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31065676 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31065107 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31064886 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31063649 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31062740 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31062130 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31060855 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31059816 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31059199 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31058533 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31058088 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31058079 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31056731 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31056729 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31054893 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31054544 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31054497 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31051723 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31051700 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31051693 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31050693 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31048689 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31048548 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31048499 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31047861 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31044426 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31043256 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31043246 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31042674 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31042629 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31042264 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31041834 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31040916 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31040697 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31039200 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31038238 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31037441 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31036508 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31036005 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31034104 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31033100 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31032472 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31032231 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31032094 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31031216 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31030485 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31028365 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31027751 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31027740 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31026246 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31026111 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31025747 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31025390 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31024839 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31024343 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31023480 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31021835 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31021538 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31021028 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31020608 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31019203 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31016954 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31016879 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31016725 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31015455 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31015311 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31015309 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31013837 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31013183 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31010898 }, { "referenced_by": [ "VarSome AI", "CIViC" ], "pub_med_id": 31010895 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31008436 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31007747 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31006774 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31006665 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31002424 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 31002229 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30999281 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30998207 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30997532 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30996911 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30995742 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30994353 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30993022 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30992297 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30990915 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30989623 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30989459 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30988823 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30988160 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30988079 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30987999 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30987478 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30987166 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30987032 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30983459 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30982079 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30981794 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30981604 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30981540 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30981109 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30980281 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30979895 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30978703 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30977771 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30977681 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30977659 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30977242 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30976712 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30976593 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30975894 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30975211 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30973654 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30972766 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30972500 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30972290 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30971321 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30969158 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30967421 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30963570 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30963391 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30963251 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30962964 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30962857 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30962505 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30959471 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30956763 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30955995 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30955264 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30954552 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30952717 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30952563 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30951807 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30950075 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30949991 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30949353 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30946937 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30946933 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30945965 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30945755 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30945443 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30944613 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30942107 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30942060 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30941953 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30941946 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30940124 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30939167 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30939097 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30937985 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30937513 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30937392 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30936351 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30936219 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30936198 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30935124 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30934988 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30934534 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30934117 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30932365 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30930275 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30929607 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30929378 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30928620 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30926642 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30926357 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30925943 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30925905 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30925466 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30924609 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30923995 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30923800 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30923702 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30923093 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30922269 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30920401 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30919552 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30918950 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30917459 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30917298 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30916170 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30915113 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30914311 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30912334 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30911424 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30909992 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30908307 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30906913 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30906321 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30905807 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30903583 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30900987 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30900145 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30900082 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30899610 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30899440 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30899313 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30897975 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30897539 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30896620 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30896556 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30896061 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30893857 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30892987 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30890564 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30890403 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30889301 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30886831 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30885850 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30885146 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30884810 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30884760 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30884463 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30883505 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30881489 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30881348 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30881123 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30878600 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30877101 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30877063 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30876455 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30875124 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30874312 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30873641 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30872781 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30872385 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30870272 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30870269 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30870099 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30869573 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30868471 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30868412 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30867592 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30865548 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30865489 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30865033 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30863114 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30862713 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30858928 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30858377 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30857358 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30854932 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30854646 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30854639 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30854087 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30854056 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30853326 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30852924 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30852641 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30851981 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30850937 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30848347 }, { "referenced_by": [ "PanelApp" ], "pub_med_id": 30847515 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30847387 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30845115 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30843305 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30843125 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30842599 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30842597 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30842178 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30842127 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30842060 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30841702 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30840950 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30840593 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30840064 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30838379 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30837450 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30835257 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30834291 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30833748 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30833419 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30833299 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30831649 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30831646 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30831205 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30829059 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30829029 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30828992 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30828692 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30828569 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30826660 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30825335 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30825062 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30824801 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30824585 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30824584 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30821319 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30821092 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30820351 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30819583 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30818875 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30815911 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30815041 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30813596 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30813366 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30811774 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30811720 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30811471 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30809081 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30807786 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30806961 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30806814 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30806760 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30806748 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30806145 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30805995 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30803557 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30802315 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30802229 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30801911 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30801710 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30800314 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30799952 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30799646 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30798169 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30797775 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30797497 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30795755 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30795516 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30794926 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30793515 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30792807 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30792691 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30792639 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30792536 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30792348 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30792255 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30792047 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30791119 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30788663 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30788603 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30785889 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30785650 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30784243 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30782837 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30782616 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30782614 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30782542 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30782386 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30782032 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30779850 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30779134 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30778775 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30776583 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30776432 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30775150 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30774680 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30773536 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30772300 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30771009 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30770994 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30770389 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30768848 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30766819 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30765391 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30765198 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30762279 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30761750 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30760858 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30760304 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30758924 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30758923 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30758881 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30758123 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30756014 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30754153 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30753828 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30753821 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30747050 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30745871 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30744692 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30744664 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30742860 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30742119 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30741938 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30741840 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30739887 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30739527 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30739334 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30738990 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30738693 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30737541 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30737244 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30736195 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30736186 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30736153 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30735919 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30735560 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30734348 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30733375 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30733075 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30732632 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30731208 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30730779 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30728904 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30728057 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30726946 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30725414 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30723297 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30723113 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30723092 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30721788 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30719722 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30719207 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30719102 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30718660 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30718460 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30718357 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30718231 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30717910 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30717908 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30717896 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30717768 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30717187 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30716341 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30713134 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30712867 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30711966 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30710723 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30710203 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30710146 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30709910 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30709805 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30707374 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30704174 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30704164 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30702508 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30700936 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30698770 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30697281 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30694737 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30693488 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30693458 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30693134 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30690710 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30690295 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30690294 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30689692 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30688762 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30688735 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30687060 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30685613 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30683711 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30682328 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30681641 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30680261 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30680072 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30679688 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30679175 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30679085 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30678281 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30677858 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30675668 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30674989 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30673109 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30672666 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30668525 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30667539 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30666518 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30665926 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30664990 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30664823 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30664692 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30664687 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30664316 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30662871 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30662627 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30662270 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30661164 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30661097 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30661020 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30659691 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30659494 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30659267 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30658510 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30657954 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30655754 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30654768 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30654714 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30654190 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30653256 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30653166 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30653029 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30652516 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30652029 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30651933 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30651927 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30651680 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30651601 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30650287 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30648628 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30646278 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30645729 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30645724 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30645670 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30643016 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30642913 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30642457 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30640733 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30640701 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30638691 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30638071 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30636389 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30636374 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30636236 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30636079 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30635874 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30635632 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30635590 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30634993 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30632125 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30631106 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30630828 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30630714 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30630516 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30629215 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30628057 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30626916 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30626368 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30625264 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30624446 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30623420 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30623365 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30623363 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30623224 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30622805 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30622172 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30620941 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30620446 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30620391 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30618001 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30616515 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30615595 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30615123 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30613980 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30612269 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30611946 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30611716 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30611619 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30609054 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30607792 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30605998 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30605831 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30605822 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30605742 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30605727 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30605687 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30604035 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30603728 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30603699 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30602616 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30601876 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30601445 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30601402 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30601377 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30601209 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30599278 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30598662 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30598499 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30598409 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30598357 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30595807 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30595535 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30592501 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30592330 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30591482 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30591192 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30590946 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30588251 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30588020 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30586191 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30584330 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30582770 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30582484 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30580112 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30579838 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30577709 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30577494 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30575961 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30575814 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30575721 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30574432 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30573850 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30572540 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30570831 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30570705 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30569607 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30569573 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30568941 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30568222 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30565721 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30565585 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30565584 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30565583 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30565582 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30565013 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30563938 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30563872 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30563395 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30562855 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30562355 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30562218 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30561760 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30561708 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30561173 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30559933 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30559419 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30559073 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30558661 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30558563 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30557911 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30557172 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30556601 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30556435 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30556047 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30555743 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30554192 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30552739 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30552700 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30551515 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30550954 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30550927 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30550736 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30550694 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30550687 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30550608 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30550190 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30549033 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30547202 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30546949 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30546944 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30546839 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30546467 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30546443 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30545990 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30544743 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30544177 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30543563 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30543471 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30542733 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30541787 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30541319 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30541168 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30541138 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30539505 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30539168 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30536719 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30535864 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30534813 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30533116 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30533005 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30532003 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30531837 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30527396 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30523048 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30521084 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30521064 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30520799 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30519308 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30518486 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30517658 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30514065 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30513023 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30509319 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30509240 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30509087 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30508500 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30508167 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30508156 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30507327 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30505580 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30505575 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30505499 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30504104 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30504064 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30503930 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30503528 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30501571 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30501565 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30501438 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30499814 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30499772 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30498021 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30496796 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30489659 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30489553 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30488863 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30488430 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30488019 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30487948 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30487126 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30485130 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30482853 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30482852 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30481565 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30481508 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30481321 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30481266 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30478887 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30478450 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30476968 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30476540 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30475255 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30474648 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30474563 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30474476 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30473900 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30472815 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30472213 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30471762 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30471144 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30470264 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30467535 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30467381 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30467046 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30466862 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30465798 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30465258 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30464690 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30464041 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30463788 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30463680 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30462564 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30462361 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30462160 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30460579 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30460421 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30459994 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30459939 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30459929 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30459475 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30458818 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30458197 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30457212 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30455751 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30454717 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30449496 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30448733 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30443187 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30442523 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30442274 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30430609 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30430550 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30430236 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30429474 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30429107 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30429031 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30428063 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30427914 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30426827 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30426665 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30423605 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30423075 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30422746 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30422243 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30422156 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30421554 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30421536 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30417961 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30416987 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30416750 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30414980 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30414707 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30414169 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30412858 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30412224 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30412106 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30410366 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30410077 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30410004 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30407895 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30407098 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30406811 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30406758 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30406424 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30405888 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30405853 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30404567 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30404005 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30401712 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30400954 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30400750 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30399198 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30398985 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30398411 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30396937 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30396366 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30396219 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30396186 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30396063 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30394984 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30393817 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30393007 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30389658 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30388854 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30388256 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30388045 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30387922 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30386910 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30385823 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30384563 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30383888 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30383722 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30383642 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30383630 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30381334 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30376465 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30376464 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30374901 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30374428 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30373548 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30370522 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30365150 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30364934 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30363424 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30361901 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30361900 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30361395 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30361170 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30360391 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30359577 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30357465 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30356899 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30356857 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30355677 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30355600 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30354850 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30353228 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30353166 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30352403 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30352402 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30351999 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30348783 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30348712 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30348606 }, { "referenced_by": [ "VarSome AI" ], "pub_med_id": 30348504 },